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____________________________________________RESUMO______________________________________________ 
RESUMO  
 
As infeções causadas por helmintas são uma das principais causas de morbidez 
e mortalidade a nível mundial. Ao longo dos anos têm sido desenvolvidas diversas 
estratégias de controlo com intuito de bloquear a sua transmissão e reduzir a carga 
parasitária associada às infeções. Apesar disso, a opistorquíase e esquistossomose 
urogenital (UGS), que foram o foco da presente tese, continuam a ser um problema 
de saúde pública nos países onde os parasitas são endémicos. Os agentes infeciosos 
causadores destas infeções, Schistosoma haematobium e Opisthorchis viverrini são 
reconhecidos pela Agência Internacional de Investigação em Cancro como causas 
definitivas de cancro. A infeção causada pelos parasitas origina o desenvolvimento de 
cancro das células escamosas da bexiga e colangiocarcinoma, respetivamente. No 
entanto, o mecanismo celular e/ou molecular que associam a opistorquíase e UGS 
com cancro permanecem desconhecidos. Possivelmente, o desenvolvimento de 
cancro associado a estas infeções helmínticas é um processo multifatorial. 
Recentemente, metabolitos de estrogénio e/ou oxiesterois na forma de catecol e os 
seus respetivos aductos de DNA têm sido implicados, como iniciadores de 
carcinogénese promovida por estes parasitas. Um dos principais focos da presente 
tese de doutoramento foi providenciar um conhecimento mais profundo do papel dos 
metabolitos que derivam dos parasitas no desenvolvimento de cancro associado às 
infeções causadas por S. haematobium e espécies de Opisthorchis. Durante o 
trabalho realizado no âmbito da tese foram obtidas diversas evidências através da 
utilização de cromatografia líquida acoplada à espectroscopia de massa, que 
suportam o postulado previamente estabelecido. Evidências essas que incluem a 
presença de metabolitos de estrogénios, aductos de DNA e derivados de 8-oxodG 
presentes na urina de 40 pacientes angolanos diagnosticados com UGS; assim como, 
a presença de diversos metabolitos de oxiesterol semelhante aos descritos para o O. 
viverrini nos estágios de desenvolvimento de Opisthorchis felineus, um parasita 
filogeneticamente próximo do O. viverrini, mas considerado não carcinogénico. Por 
outro lado, evidências da interação dos metabolitos parasitários com DNA do 
hospedeiro formando aductos de DNA, foram detetadas em amostras biológicas de 
hamster experimentalmente infetados com O. felineus. Ademais, estudos 
histopatológicos demonstraram que a opistorquíase felinea proporciona um ambiente 
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____________________________________________RESUMO______________________________________________ 
celular favorável para o desenvolvimento de um nicho pré-cancerígeno, pelo menos 
no modelo animal. Nesta tese, também se comprovou a capacidade de compostos 
semelhantes aqueles descritos para opistorquíase e esquistossomose, em interagir 
com DNA in vitro formando aductos de DNA. A consonância destes resultados 
parecem suportar a premissa que designa os metabolitos de oxiesterois e/ou 
estrogénios na iniciação de carcinogéneses através da indução de danos de DNA. 
Atualmente, a terapia para estas infeções helmínticas depende de um único 
fármaco, praziquantel, que apenas têm como alvo o parasita e não as patologias 
associadas com a infeção. Com intuito de melhorar a atual terapia, desenvolveu-se 
uma nova estratégia terapêutica baseada na reposição de fármacos e combinação de 
fármacos com antioxidantes. O principal objetivo desta terapia é não só eliminar os 
parasitas, mas melhorar as condições patológicas associadas às infeções e em última 
análise contrariar o processo de carcinogénese. Assim, recorreu-se ao uso de 
antioxidantes que devido às suas propriedades biológicas poderão ser úteis para inibir 
a formação de metabolitos putativamente carcinogénicos e bloquear o processo de 
carcinogénese. Na avaliação da eficácia desta estratégia realizaram-se diversos 
ensaios in vitro utilizando as fases larvais e vermes adultos. O recurso à microscopia 
ótica e de transmissão eletrónica permitiram observar e quantificar o efeito da nova 
estratégia terapêutica em eliminar os parasitas. Os resultados demonstraram que não 
só os antioxidantes por si apresentaram atividade contra as formas larvais e vermes 
adultos como quando usados em combinação potenciaram a atividade dos fármacos. 
Adicionalmente, utilizando técnicas de cromatografia líquida acoplada à 
espectroscopia de massa foi possível realizar estudos relativos ao efeito inibitório da 
nova estratégia terapêutica na formação de metabolitos previamente associados a 
esquistossomose e opistorquíase. Com este estudo foi possível demonstrar que 
combinação de fármaco+antioxidante resulta na inibição quase completa na formação 
de metabolitos in vitro o que pode ser importante no contexto da prevenção da 
iniciação a carcinogénese associada às infeções mencionadas.  
Os resultados apresentados no âmbito da presente tese de doutoramento 
originaram uma melhor compreensão dos mecanismos moleculares envolvidos na 
carcinogénese associada a estas doenças helmínticas. Adicionalmente, revelam que 
a nova estratégia terapêutica, através da combinação fármacos com antioxidantes, 
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____________________________________________RESUMO______________________________________________ 
pode ser uma ferramenta valiosa e útil para o combate das mesmas e as suas 
consequências. 
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____________________________________________ABSTRACT___________________________________________ 
ABSTRACT 
 
Helminth infections are one of the major leading causes of morbidity and mortality 
worldwide. Several control strategies to block their transmission and reduce the burden 
associated to infections. Despite that, opisthorchiasis and schistosomiasis urogenital 
(UGS), which will be our focus, remain a public health problem in endemic countries. 
The causative agents of these infections, Schistosoma haematobium and Opisthorchis 
viverrini, are recognized as definitive cause of cancer by International Agency 
Research on Cancer: infection with these parasites leads to squamous cell carcinoma 
and cholangiocarcinoma, respectively. However, the cellular and/or molecular 
mechanisms linking opisthorchiasis and UGS with cancer remain elusive. Most likely, 
the development of S. haematobium and O. viverrini infection-associated cancer is a 
multistep and multifactorial process. Nonetheless, estrogen and/or oxysterol 
metabolites in form of catechol and DNA adducts have been implicated, at least in part, 
as initiators of carcinogenesis promoted by these parasites. One of focus of this 
doctoral thesis was provided deeper understanding of the role of parasite-derived 
metabolites in the development of cancer associated with S. haematobium and 
Opisthorchis spp. infections. Several evidences by liquid chromatography coupled to 
mass spectrometer (LC-MS/MS) obtained during the thesis support our previously 
postulated. Urine analysis of angolan patients demonstrated the presence of estrogen-
like metabolites, DNA adducts and derivatives of 8-oxo-dG. Additionally, 
developmental stages of O. felineus, a closely phylogenetic relative of O. viverrini 
considered non carcinogenic, presented several oxysterol-like metabolites similar to 
those described for O. viverrini. Evidences of their interaction with host DNA, e.g. DNA 
adducts, were observed in biological samples from hamster experimental infection. 
Moreover, histopathological studies demonstrated that infection with O. felineus lead 
to developmental of a pre-niche cancerous, at least in rodent model, raising question 
about its carcinogenic potential. In this thesis, we also prove the ability of compounds, 
similar to those described for opisthorchiasis and schistosomiasis, to interact with DNA 
in vitro leading to formation of DNA-adducts. The consonance of these results seems 
to support the premise that assign the oxysterol- and estrogen-like metabolites in the 
initiation of carcinogenesis through DNA damage. 
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____________________________________________ABSTRACT___________________________________________ 
Until now, the therapy against these helminth infections relies on a single drug, 
praziquantel, that mainly targets the parasite and not the pathologies associated with 
the infection. In order to improve the current therapy, we developed a novel therapeutic 
approach based on drug repurposing and combination of drugs with antioxidants. The 
aim of this novel therapeutic approach is not only eliminating the parasites but also 
ameliorate the infection-associated pathologies and ultimately counteract the 
infections-associated carcinogenesis. Thus, the antioxidants were selected due to their 
biological properties which might be useful to potentially inhibit the formation of putative 
carcinogenic metabolites and block carcinogenesis. In order to assess its efficacy, we 
performed several in vitro assays either in larval and adult worms. Light and 
transmission electron microscopy allowed us to observe and quantified the effect of 
novel therapeutic approach in eliminating the parasite. Not only antioxidant per se 
demonstrated antischistosomal activity against larvae and adult worms but also when 
combined to drugs enhance their activity. Moreover, using LC-MS/MS was possible to 
study the inhibitory effect of novel therapeutic approach in formation of metabolites 
previously associated to schistosomiasis and opisthorchiasis. The results revealed that 
combination of drug+antioxidant leads to almost a complete formation of metabolites 
which might be important in context of prevention the initiation of opisthorchiaisis and 
UGS-associated carcinogenesis. 
The results presented in this doctoral thesis open avenues to a better 
understanding of the molecular mechanisms involved in carcinogenesis induced by 
opisthorchiasis and UGS. Furthermore, revealed that novel therapeutic approaches 
that combined drugs with antioxidants might be valuable to combat these helminth 
diseases and its dreadful consequences.  
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________________________________________ ABBREVIATIONS ______________________________________ 
ABBREVIATIONS 
8-oxodG – 8-oxo-7,8-dihydro-2’-deoxyguanosine 
ABZ – Albendazole  
AIDS – Acquired immune deficiency syndrome 
ART – Artemether  
AS – Artesunate  
BilIN – Biliary intraepithelial neoplasia  
Ca2+ – ion calcium 
CCA – Cholangiocarcinoma 
CEQ – Catechol estrogen quinones 
CHO – Chinese hamster ovary cells 
CI – Combination index  
COMT – Catechol-O-methyltransferase 
CTZ – Clotrimazole  
Curc – Curcumin 
DALYs – Disability-adjusted life years  
DiPept – H-L-Tryp-L-Ser-OH, Dipeptide 
ELISA – Enzyme-linked immunoabsorbent assay  
GSH – Gluthatione-S-transferase 
FBZ – Flubendazole 
FGS – Female genital schistosomiasis 
Flav – Flavone 
IARC – International Agency for Research on Cancer  
IL-6 – Interleukin-6 
IMT – Imatinib 
INSA – Instituto Nacional de Saúde Dr. Ricardo Jorge 
LC-MS/MS – Liquid chromatography coupled to mass spectrometry 
MBZ – Mebendazole  
MCZ – Miconazole  
MDA – Mass drug administration  
MEL – Melatonin 
MFQ – Mefloquine 
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NEM – Newly excysted metacercaria 
NDMA – N-dinitrosomethylamine 
NTD – Neglected tropical diseases  
NQO1 – Quinone reductase 
NTS – Newly transformed schistosomula  
OXA – 4-phenyl-1,2,5-oxadiazole-3-carbonile-2-oxide  
PDR – People’s Democratic Republic  
PZQ – Praziquantel  
Resv – Resveratrol  
SCC – Squamous cell carcinoma 
TBD – Tribendimine  
TEM – Transmission electron microscopy  
TGR – Thioredoxin glutathione reductase  
TMT – Trametanib 
UGS – Urogenital schistosomiasis 
VDT – Vandetanib 
WHO – World Health Organization  
XTH – Xanthohumol  
 
 
 
 
 
 
 
 
 
 
NOVEL THERAPEUTICS APPROACH AGAINST SCHISTOSOMA HAEMATOBIUM AND OPISTHORCHIS 
VIVERRINI AND ASSOCIATED CANCERS (BLADDER CANCER AND CHOLANGIOCARCINOMA) 
XVIII 
 
________________________________________ LIST OF FIGURES _____________________________________ 
LIST OF FIGURES 
Figure I-1. Adult worms of schistosome coupled. ...................................................... 5 
Figure I.2. The developmental cycle of the three main species that infect humans: S. 
mansoni, S. haematobium, and S. japonicum. ........................................................... 7 
Figure I.3.  Worldwide distribution of schistosomiasis considering the prevalence rate.
 ................................................................................................................................. 10 
Figure I-4. Morphology of adult worms of a) Opisthorchis felineus and b) Opisthorchis 
viverrini ..................................................................................................................... 14 
Figure I-5. Developmental cycle of the liver flukes Opisthorchis viverrini and 
Opisthorchis felineus. ............................................................................................... 15 
Figure I-6. a) Global geographical distribution of Opisthorchis viverrini and 
Opisthorchis felineus infections. ............................................................................... 18 
Figure I-7. Schematic representation of multifactorial processes that can contribute to 
the development of the biliary and bladder/urogenital tract cancers resulting from 
infection with the liver fluke O. viverrini and S. haematobium ................................... 26 
Figure I.8. Metabolites excreted from parasites are highly reactive and might interact 
with host DNA leading to formation of DNA adducts ................................................ 30 
Figure I-9. Postulated of chemical carcinogenesis mediated by oxysterols and 
estrogen-like metabolites derived from O. viverrini and S. haematobium. ................ 31 
Figure I.10. Metabolism of PZQ mediated by family of CYP450 enzymes. .............. 34 
Figure II-1. Novel therapeutic approach and desire effects against opisthorchiasis and 
schistosomiasis. ....................................................................................................... 76 
  
 
 
 
  
 
NOVEL THERAPEUTICS APPROACH AGAINST SCHISTOSOMA HAEMATOBIUM AND OPISTHORCHIS 
VIVERRINI AND ASSOCIATED CANCERS (BLADDER CANCER AND CHOLANGIOCARCINOMA) 
XIX 
 
________________________________________ LIST OF TABLES _______________________________________ 
 
LIST OF TABLES 
 
Table I.1. Schistosoma species and regions of prevalence of schistosomiasis.......... 9 
NOVEL THERAPEUTICS APPROACH AGAINST SCHISTOSOMA HAEMATOBIUM AND OPISTHORCHIS 
VIVERRINI AND ASSOCIATED CANCERS (BLADDER CANCER AND CHOLANGIOCARCINOMA) 
 XX 
 
_____________________________________ TABLE OF CONTENTS ___________________________________ 
TABLE OF CONTENTS 
 
ACKNOWLEDGMENTS .................................................................................................. VII 
LIST OF PUBLICATIONS ................................................................................................. IX 
RESUMO ..................................................................................................................... XI 
ABSTRACT ................................................................................................................ XIV 
ABBREVIATIONS ........................................................................................................ XVI 
LIST OF FIGURES ..................................................................................................... XVIII 
LIST OF TABLES ......................................................................................................... XIX 
TABLE OF CONTENTS .................................................................................................. XX 
Section I - Introduction and Generalities ................................................................ 1 
1. Schistosoma and Opisthorchis: threatening helminth parasites ........................... 3 
1.1. The blood fluke Schistosoma and associated infection .............................. 3 
1.1.1. Morphology and biology of parasite ..................................................... 3 
1.1.2. History of schistosomiasis ................................................................... 8 
1.1.3. Schistosomiasis: an overview .............................................................. 9 
1.1.3.1. Urogenital schistosomiasis: clinical presentation ......................... 11 
1.1.3.2. Diagnostic of urogenital schistosomiasis ...................................... 12 
1.1.4. Biological carcinogenic aspect of Schistosoma haematobium ........... 13 
1.2. Liver fluke Opisthorchis viverrini: infection and carcinogenic potential ..... 13 
1.2.1. Morphological and biological aspects of parasite .............................. 13 
1.2.2. Historical review of opisthorchiasis .................................................... 16 
1.2.3. Opisthorchiasis: from geographical distribution to clinical 
presentation…… ............................................................................................ 17 
1.2.3.1. Pathology and pathogenesis ........................................................ 20 
1.2.3.2. Diagnosis of opisthorchiasis ......................................................... 21 
1.2.4. Opisthorchis spp., major risk for development of 
cholangiocarcinoma…… ................................................................................ 22 
NOVEL THERAPEUTICS APPROACH AGAINST SCHISTOSOMA HAEMATOBIUM AND OPISTHORCHIS 
VIVERRINI AND ASSOCIATED CANCERS (BLADDER CANCER AND CHOLANGIOCARCINOMA) 
XXI 
 
_____________________________________ TABLE OF CONTENTS ___________________________________ 
2. Helminths and infection-associated cancer ........................................................ 23 
2.1. Risk factors leading to bladder cancer and cholangiocarcinoma associated 
to helminth infections ......................................................................................... 24 
2.2. Evidences of parasitic catechol estrogens and oxysterol-like metabolites 
associated to helminth infection ......................................................................... 27 
3. Current treatment and control for schistosomiasis and opishtorchiasis: a single 
drug ........................................................................................................................ 33 
4. Alternative therapeutic approaches against schistosomiasis and 
opisthorchiasis…… ................................................................................................. 36 
4.1. Drug repurposing and combination of drugs ............................................ 36 
4.2. Antioxidant biomolecules: a promising alternative? .................................. 41 
5. References ......................................................................................................... 44 
Section II – Aims of doctoral thesis ...................................................................... 73 
1. Aims of doctoral thesis ....................................................................................... 75 
2. References ......................................................................................................... 77 
Section III – Results ................................................................................................ 79 
CHAPTER 1. Estrogen-like metabolites and DNA-adducts in urogenital 
schistosomiasis-associated bladder cancer. .......................................................... 83 
CHAPTER 2. Infection with Opisthorchis felineus induces intraepithelial neoplasia of 
the biliary tract in a rodent model. .......................................................................... 95 
CHAPTER 3. Infection with carcinogenic helminth parasites and its production of 
metabolites induces the formation of DNA-adducts .............................................. 109 
CHAPTER 4. The antioxidants resveratrol and N-acetylcysteine enhance anthelmintic 
activity of praziquantel and artesunate against Schistosoma mansoni. ................ 123 
CHAPTER 5. Combination anthelmintic/antioxidant activity against Schistosoma 
mansoni ................................................................................................................ 139 
CHAPTER 6. Combination of antioxidants with drug repurposed against adult worms 
of Schistosoma mansoni ...................................................................................... 163 
NOVEL THERAPEUTICS APPROACH AGAINST SCHISTOSOMA HAEMATOBIUM AND OPISTHORCHIS 
VIVERRINI AND ASSOCIATED CANCERS (BLADDER CANCER AND CHOLANGIOCARCINOMA) 
XXII 
 
_____________________________________ TABLE OF CONTENTS ___________________________________ 
CHAPTER 7. Inhibition of the formation in vitro of putatively carcinogenic metabolites 
derived from S. haematobium and O. viverrini by combination of drugs with 
antioxidants .......................................................................................................... 187 
Section IV – Discussion ....................................................................................... 201 
1. General discussion ........................................................................................... 203 
2. References ....................................................................................................... 213 
Section V – Conclusions and future perspectives ............................................ 219 
1. Main findings and conclusions of the PhD project ............................................ 221 
2. Future perspectives .......................................................................................... 222 
Section VI – Appendix .......................................................................................... 225 
Appendix 1 – The role of estradiol metabolism in urogenital schistosomiasis-induced 
bladder cancer ...................................................................................................... 227 
Appendix 2 – Praziquantel for schistosomiasis: single-drug metabolism revisited, 
mode of action, and resistance ............................................................................. 241 
Appendix 3 – Drug repurposing for schistosomiasis: combinations of drugs or 
biomolecules ........................................................................................................ 259 
Appendix 4 – Support information of scientific article presented in Section III – 
Chapter 3 .............................................................................................................. 295 
Appendix 5 – Support information of scientific article presented in Section III – 
Chapter 6 .............................................................................................................. 307 
Appendix 6 – Support information of scientific article presented in Section III – 
Chapter 7 .............................................................................................................. 311 
Appendix 7 – Spectrometric profiles liver flukes Opisthorchis and Fasciola provide 
insight into infection-induced carcinogenesis ....................................................... 319 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section I 
Introduction and Generalities 
  
NOVEL THERAPEUTICS APPROACH AGAINST SCHISTOSOMA HAEMATOBIUM AND OPISTHORCHIS 
VIVERRINI AND ASSOCIATED CANCERS (BLADDER CANCER AND CHOLANGIOCARCINOMA) 
 3 
 
_________________________________ SECTION I. INTRODUCTION _______________________________ 
I. Introduction and Generalities  
1. Schistosoma and Opisthorchis: threatening helminth parasites 
Helminth infections are one of the major leading causes of morbidity and mortality 
worldwide and are prominent among the so-called neglected tropical diseases (NTDs). 
It is estimated that almost two billion people worldwide are infected with helminth 
parasites. These parasites are among the most common infectious agents nowadays 
and are responsible for several debilitating diseases and syndromes (Hotez et al., 
2008; Hotez, 2011; McSorley and Maizels, 2012). Generally, helminth infections are 
most prevalent in rural communities among tropics and subtropics where sanitation 
conditions are inappropriate (Hotez, 2011). Despite many efforts to eradicate them, 
this remains a distant goal due to many factors as a lack to effective treatment, limited 
pharmacological efficacy, emerging drug resistance, and rapid reinfection in 
environments where the transmission cannot or is very difficult to interrupt (McSorley 
and Maizels, 2012). Two important classes of helminths are responsible for the most 
common and dreadful infections: the nematodes and platyhelminths (also known as 
flatworms) that include the flukes of genus Schistosoma and Opisthorchis (Hotez et al., 
2008).  
 
1.1. The blood fluke Schistosoma and associated infection 
1.1.1. Morphology and biology of parasite 
The genus Schistosoma belongs to the Phylum Platyhelminths, Class Trematoda, 
Subclass Digenea, Order Schistosomatida and Family Schistosomatidae (Rollinson 
and Southgate, 1987; Alarcón de Noya and Noya, 2008). Three schistosome species 
are responsible for the majority of human infections: Schistosoma mansoni, S. 
haematobium, S. japonicum. Other two species are also able to infect human, S. 
intercalatum and S. mekongi (Gryssels et al., 2006; Cook and Zumla, 2009; Colley et 
al., 2014; Coltart and Whitty, 2015).  
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The parasites comprehend several developmental stages: eggs, miracidia, 
sporocysts, cercariae, schistosomula and adult worms. The adult schistosome has a 
cylindrical tubular elongated body (7-20 mm) that features two rudimentary suckers 
(oral and ventral), a complex tegument, a blind digestive tract and reproductive organs 
(Figure I-1). Schistosome tegument, a living syncytium, is one of the most important 
organs due to its role in protection against the immune attack of the host, nutrients 
absorption and molecules, and proteins synthesis (Braschi et al., 2006; Skelly and 
Wilson, 2006; van Hellemon et al., 2006). Parasite produce energy via glucose 
metabolism from the host through digestion of erythrocytes; which why this helminth is 
also known as blood fluke (van Oordt el al., 1985; Barret, 2009). The digest system of 
schistosomes is rudimentary with a blind digestive tract and consequently, they cannot 
excrete waste products, so they regurgitate them into the bloodstream. These products 
are useful for blood and urine-based diagnostic assays of schistosome infection as 
further describe in this section (Colley et al., 2014). Schistosomes are dioecious and 
not hermaphroditic like the other trematodes (Figure I.1) (Loker and Brant, 2006). 
Males are shorter and stouter than females and presented a gynecophoral canal in 
which female lies, thus, adult worms live in copula much of the time (Gryssels et al., 
2006; Colley et al., 2014; Coltart et al., 2015). Adult worms are long-lived and can 
survive in their mammalian host usually 3 to 10 years but in some cases can survive 
up to 40 years (Colley et al., 2014). During this period the female produces eggs and 
fertilized them. Similar to energy production, egg rate production is dependent on fatty 
acid oxidation derived from the host (Huang et al., 2012). 
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Figure I-1. Adult worms of schistosome coupled. Both worms presented oral and ventral suckers. 
Female (♀) reside inside gynecophoral canal of male (♂). The tegument of male adult worms is fully 
covered with spines. (Image adapted from Trustees of the Natural History Museum 
http://www.nhm.ac.uk consulted on 31st July 2019). 
The life cycle of Schistosoma spp. is complex involving two hosts: one definitive 
(humans) and intermediate (snails) (Figure I-2). Along their lifetime, females produce 
hundreds (African species: S. mansoni, S. haematobium and S. intercalatum) to 
thousands (oriental species: S. mekongi and S. japonicum) of eggs per day. The eggs 
either expelled through urine or feces remain viable up to 7 days or become trapped 
in the host tissues where they induce inflammation and die. Regardless of whether 
eggs are excreted or retained in host tissues, they die 1-2 weeks after being released 
by the female worm. The excreted eggs that reach the freshwater will hatch releasing 
the miracidium that infects a suitable snail host. Following snail infection, the 
miracidium undergoes through asexual reproduction from sporocyst stages until forms 
cercariae, and thousands of them are eventually released from the snail into the water 
after 4 to 6 weeks. After being released the cercariae can remain infective for 1 to 3 
days, however, their energy reserves considerably diminish over a few hours (Colley 
et al., 2014). Human infection occurs when cercariae, the infectious form for humans 
and other mammals, contact with the skin during washing or swimming, penetrate it 
and shed the tail. Afterwards, the juvenile larvae, schistosomula, migrate within the 
circulatory system until they reach vesicle plexus and veins that drain the ureter and 
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nearby pelvic organs (S. haematobium) or mesenteric veins (all other species), where 
the worms mature, mate and commence egg laying about 5-7 weeks post-infection 
(King, 2011; Barsoum et al., 2013; Colley et al., 2014) and thus complete the life 
cycle. Transmission invariably occurs when schistosome-infected individuals or 
mammals contaminate freshwater with their urine or feces containing parasite eggs 
(Gautret et al., 2012). Due to schistosome life cycle, the infection is considered ‘the 
most important water-based disease from a global public health perspective’ 
demonstrating the importance of water for its spread (Steinmann et al., 2006; Di Bella 
et al., 2018). 
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Figure I.2.  The developmental cycle of the three main species that infect humans: S. mansoni, 
S. haematobium, and S. japonicum. The paired adult worms’ mate and produce eggs. The egg 
morphology is useful to distinguish species of schistosomes: S. haematobium (A) and S. mansoni (B) 
produce oval eggs with sharp lateral or terminal spine, respectively; S. japonicum produce round eggs 
with a rudimentary lateral spine (C). The eggs also vary slightly in size: S. mansoni (115-175 x 45-70µm) 
and S. haematobium (110-170 x 40-70µm) eggs have similar size while S. japonicum eggs are smaller 
(70-100 x 50-70µm). The eggs reach the freshwater release miracidium which infects suitable snails: a) 
Onchomelania for S. japonicum; b) Bioamphalaria glabrata for S. mansoni and c) Bulinus for S. 
haematobium. After asexual reproduction the snail release cercariae that when in contact with human 
skin releases schistosomula which enter to the bloodstream and travel until reach the organ where 
parasite resides and mature. (Image adapted from Vale et al., 2017a). 
The parasite Schistosoma not only infect humans, but some species as S. 
japonicum and S. mekongi are also zoonotic and can infect several other mammals 
including dogs, cattle, or pigs. Despite species as S. mansoni and S. haematobium are 
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capable of infect animals as rodent and non-human primates, human beings are 
considering its predominant mammals’ hosts. To successfully control and elimination 
of the human schistosomiasis it is crucial to comprehend the life cycle and the 
parasite’s movement between the intermediate and definitive host (Colley et al., 2014). 
1.1.2. History of schistosomiasis 
At least for 6000 years ago, there is evidence of infection caused by schistosomes. 
It remains unclear where the helminth parasite first emerged. Some studies in northern 
Syrian demonstrated evidence of the presence of this helminth on human skeletal of 
farmers dated with 5800-4000 years before Christ (Anastasiou et al., 2014). 
Nonetheless, it has been suggested that helminth first appeared in African areas 
containing great lakes essential for maintaining the life cycle (Steinmman et al., 2006). 
The earliest description of schistosomiasis can be found in the ancient Assyro-
Babylonian literature, namely in the Papyrus Ebers of Egypt (Girges, 1934) where it is 
mentioned a worm disease might cause urinary bleeding. However, only in 19th-
century efforts were made to understand the life cycle of helminth and the 
pathogenesis associated with infection (Di Bella et al., 2018). The first description 
of Schistosoma spp. is attributed to German pathologist Theodor Bilharz in 1851. 
During the autopsy of a young Egyptian soldier, the pathologist found worms in portal 
veins and described the presence of eggs with a terminal spine (Bilharz, 1853a). These 
observations suggested that soldier could be infected with S. mansoni or S. 
haematobium since eggs of two species share this characteristic (Figure I-2). This 
finding was reported to his professor von Freholdtz and later presented in a meeting 
at Breslau where the pathologist described the characteristics pathologic changes and 
clinical features of schistosomiasis and named the worms as Distomium 
haematobium (Bilharz, 1853b and 1856). In 1858, Weinland disagreed with the 
nomination and suggested altering the name to Schistosoma where ‘Schisto’ means 
cavity and ‘soma’ means the body that envelops the female. Two years later, Cobbold 
(1959) suggest change the designation of infection to bilharzia in honor of Theodor 
Bilharz. Since 1964, the official nomenclature to infection caused by schistosome is 
schistosomiasis, however, in Europe and the Middle East, the term bilharzia is also 
commonly used (Olds and Dasarathy, 2001).  
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Over the following years and until nowadays, many researchers focused on 
schistosomes and its infection leading to a deeper understanding of the parasite's life 
cycle, pathology, and novel Schistosoma species. 
 
1.1.3. Schistosomiasis: an overview 
The World Health Organization (WHO) considers schistosomiasis one of the major 
NTD that mainly occurs in tropical and sub-tropical areas (Gryssels et al., 2006; Colley 
et al., 2014; McManus et al., 2018). Human schistosomiasis occurs mainly through 
infection of three schistosome species: S. haematobium induces urogenital 
schistosomiasis (UGS), while S. mansoni and S. japonicum lead to intestinal 
schistosomiasis. Infections caused by S. intercalatum and S. mekongi are only for local 
importance and also causing intestinal schistosomiasis (Gryssels et al., 2006). The 
species are distributed worldwide (Table I-1 and Figure I.3), and its distribution 
depends mainly on the ecology of snails hosts and their infection (Colley et al., 2014).  
Based on update and correct data from: (https://www.who.int/en/news-room/fact-sheets/detail/schistosomiasis - 
last access on July 31st 2019). 
Over 250 million people are infected with schistosomes worldwide, with 201.5 
million (97% of cases) of them live in Africa (Steinmann et al., 2006, Utzinger et al., 
2009; Hotez et al., 2014). About half of all infected people have symptoms with 20 
million suffer from severe consequences. It is estimated that schistosomiasis causes 
Table I.1. Schistosoma species and regions of prevalence of schistosomiasis. 
Species Region of prevalence Forms of 
schistosomiasis 
S. mansoni Africa, Middle East, Caribbean, 
Brazil, Venezuela and Suriname 
 
 
 
Intestinal schistosomiasis 
S. japonicum China, Indonesia, Phillipines 
S. mekongi Several districts of Cambodia and 
Laos People’s Democratic Republic 
S. intercalatum Rain forest areas of central Africa 
 
S. haematobium 
 
Africa, Middle East, Corsica 
(France) 
 
Urogenital schistosomiasis 
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about 280 000 deaths annually and 779 million people or more are at risk of infection 
in 76 countries (Figure I.3) (Steinmman et al., 2006; Utzinger et al., 2009; WHO, 2013). 
According to the Global Burden of Disease Study 2016, the global burden of 
schistosomiasis is estimated at 1.9 million disability-adjusted life years (DALYs) (GDB, 
2017), however, prior studies estimated the global burden of schistosomiasis at 1.7-
4.5 million DALYs which suggest that estimative might be underrated (WHO, 2002; 
Utzinger and Keiser, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.3.  Worldwide distribution of schistosomiasis considering the prevalence rate. Most of 
cases occurs on the African continent. (Figure from Map: Distribution of schistosomiasis, worldwide, 
2012, WHO, © 2012).  
Although schistosomiasis is generally restricted to the tropics and sub-tropics, 
several cases of infection have been reported in Europe. Most of them occur due to 
the arrival of infected immigrants and in returning travelers from countries where the 
infection is endemic (Lingscheid et al., 2017; Marchese et al., 2018). Between 1997 
and 2010, more than 1465 cases of imported schistosomiasis have been reported by 
the European Network for Tropical Medicine and Travel Health (Lingscheid et al., 
2017). Notably, the recent cases reported in Corsica are not related to immigrants or 
travels (Holtfreter et al., 2014; Boissier et al., 2015) suggesting the expansion of 
suitable habitats for transmission of schistosomiasis and its potential of reemerging in 
economically developed regions in southern Europe (Holtfreter et al., 2014). 
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Furthermore, recent studies point to the potential hybridization of species originating 
two novel hybrid parasites from hybridization between S. haematobium and S. 
mansoni (Le Govic et al., 2019) and species of S. haematobium and S. bovis (bovine 
blood fluke) (Moné et al., 2015; Oey et al., 2019).  
1.1.3.1. Urogenital schistosomiasis: clinical presentation 
Considering that S. haematobium resides in the urinary tract, the infection caused 
by parasite is designated urogenital schistosomiasis (UGS). Generally, the progression 
of schistosomiasis comprehends three general stages: acute, established active and 
chronic infection (McManus et al., 2018). The stages differ in egg excretion rates in 
urine as well as clinical manifestations and symptoms (McManus et al., 2018). 
The acute phase is typically characterized by an acute, pruritic, maculopapular 
eruption, cercarial dermatitis, at the site of cercarial skin penetration within the first 24h 
(Chofle et al., 2014; McManus et al., 2018). Cercarial dermatitis occurs due to a portion 
of the infectious larvae that die in the skin which triggers the innate immune response 
and give rise to hypersensitivity reactions. Following successful cercariae penetration 
and maturation, the infection may proceed to a symptomatic stage also known as 
Katayama fever or Katayama syndrome. The symptoms are caused by systemic 
hypersensitivity reactions and formation of immune complexes in response to antigens 
released during schistosomula migration and initiation of egg deposition. Most 
commons symptoms are fever, myalgia, malaise and fatigue, headache, non-
productive cough, and intestinal symptoms as abdominal tenderness or pain which 
usually appear between 2 weeks and 3 months after exposure. Interestingly, acute 
schistosomiasis is rarely observed in people living in S. mansoni or S. haematobium-
endemic areas (Gryssels et al., 2006 and 2012; Colley et al., 2014; Chofle et al., 2014; 
McManus et al., 2018). Following the initial stage, the disease reaches a stage of 
established active and chronic infection, with mature adult worms and well-established 
egg production. The symptoms and pathological alterations of chronic infection are 
closely associated with the passage of parasite eggs through the urinary bladder wall 
and egg deposition in the bladder (Gray et al., 2011). It is usually finding a cluster of 
living eggs in bladder tissues that induce intense inflammatory reaction and 
eosinophilia (Randrianasolo et al., 2015). This inflammatory reaction is required to aid 
the excretion of eggs to the environment, and the passage of eggs into the lumen of 
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the bladder commonly induce hematuria. Additionally, can result in bladder wall 
thickening and development of masses and pseudopolyps, inflammation, granulomas, 
acute and chronic pyelonephritis, hydrophenosis, kidney malfunctions, among others 
(Burki et al., 1986; Hatz et al., 1990; Kayange et al., 2014). During this stage, eggs are 
also frequently deposited in genital organs like the cervix, seminal vessels and prostate 
leading to possible lesions and inflammation (Leutscher et al., 2000; Kjetland et al., 
2006). Most of the women infected with S. haematobium also suffer from female genital 
schistosomiasis (FGS) resulted from egg deposition in uterus, vulva, and vagina and 
consequently triggers an inflammatory response that affects fertility (King, 2018). In 
men and female, the manifestation of UGS may increase HIV transmission (Ketjland 
et al., 2006). Generally, during the late chronic infections little or no detectable eggs 
are excreted, however, occurs accumulation of dead calcified tissues eggs which 
appear as yellow sandy patches in the cystoscopic examination of the bladder mucosa 
(Burki et al., 1986).  
1.1.3.2. Diagnostic of urogenital schistosomiasis 
The gold standard for UGS diagnosis is based on detection of schistosome eggs in 
urine and tissue biopsy samples. Briefly, the collected urine, usually a small amount, 
is filtered and the eggs in that volume are counted microscopically. The level of 
infection is expressed as eggs per 10 ml of urine (Katz et al., 1972; Feldmeier et al., 
1982 and 1986). However, in light infections and late chronic stage of infection, the 
method has low sensitivity (Feldmeier et al., 1986). Therefore, it is necessary to use 
alternative methods including serology for detection of schistosome antigens and anti-
schistosome-specific antibodies, and polymerase chain reaction (PCR) for detection of 
worm DNA. These methods increase the sensitivity up to 90% and allow detect the 
infection during the acute phase and low burden of infection (Van Lieshout et al, 1997; 
van Dam et al., 2013; Meurs et al., 2015; He et al., 2018; Grenfell et al., 2018). 
Besides laboratory techniques, immunological diagnosis is a valuable 
complementary tool that has been used in population-based studies for >20 years. 
Ultrasonography can be used to visualize pathological changes and monitoring the 
direct effect of interventions on morbidity associated with infection. Nowadays, 
standardized protocols that allow classified and grade the pathological lesions are 
already available (Barata et al., 1999; Chigusa et al., 2006). 
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1.1.4. Biological carcinogenic aspect of Schistosoma haematobium 
About two-thirds of the 90% of schistosomiasis in Africa are caused by S. 
haematobium, the only Schistosoma specie considered as group 1 biological 
carcinogenic by International Agency for Research on Cancer (IARC) (IARC, 2012).  
The infection caused by S. haematobium, UGS, is associated with the risk of 
development of squamous cell carcinoma (SCC) of the bladder (Vennervald et al., 
2009, IARC 2012). Indeed, bladder cancer is a frequent and dire complication of 
chronic UGS. Bladder cancer may be a consequence of many years of exposure to 
parasite, infection and urinary tract inflammation (Vennervald et al., 2009) due to 
continuous oviposition by the parasite (McManus et al., 2018). As mentioned, parasite 
eggs excrete several metabolites to transverse the bladder, yet, about half the eggs 
remain trapped on vesical mucosa causing inflammatory responses that not only 
conducted to haematuria but other serial clinical conditions such as urothelial dysplasia, 
hyperplasia and ultimately bladder cancer (Honeycutt et al., 2014). Case reports 
indicate that patients with UGS may develop bladder cancer earlier than uninfected 
people (Mostafa et al., 1999; Herrera et al., 2005; Porta et al., 2011). However, the 
cellular and/or molecular mechanism linking S. haematobium infection with 
carcinogenesis remain elusive. Further, in this section, it will be discussed the possible 
mechanisms of carcinogenesis associated with UGS.  
1.2. Liver fluke Opisthorchis viverrini: infection and carcinogenic 
potential 
1.2.1. Morphological and biological aspects of parasite 
Opisthorchis spp. are liver fluke parasites that also belong to the Phylum of 
Platyhelminths and class Trematoda but differ from schistosomes on subclass 
(Digenea), family (Opisthorchiidae), and genus (Opisthorchis). Opisthorchis 
viverrini and O. felineus, also known as the Southeast Asian liver fluke and as the cat 
liver fluke, respectively, are epidemiologically significant species (Beaver et al., 1984). 
These parasites are zoonotic and affect both human and animal liver and bile ducts 
(Keiser and Utzinger, 2005; Petney et al., 2013; Pakharukova and Mordvinov, 2016). 
Similar to schistosome species, opisthorchiids comprehends several developmental 
stages including eggs, miracidia, sporocysts, cercariae, metacercariae and adult 
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worms (Utzinger and Keiser, 2005). The adult forms present a flat body, leaf-shaped, 
transparent within about 10-25 mm in length and 3-5 mm in width, covered with a 
noncellular cuticle, two oral suckers, excretory bladder, and reproductive organs 
(Figure I-4) (Sripa et al., 2008). These parasites are hermaphrodite flukes that 
reproduce by self-fertilization (Yossepowitch et al., 2004). They have two testicles 
situated near the posterior extremity and a multilobate ovary in front of the anterior 
testicles (Ash and Oreil, 2007). The lifespan of adult worms is up to 25-30 years and 
during that period they produce an estimated 50–200 eggs/g of feces/day (Sithithaworn 
and Haswell-Elkins 2003; Sripa and Pairojkul, 2008). Eggs are ovoid with a yellowish-
brown colour and have a distinct operculum, which opens to release the miracidium, a 
fully developed larva. In average, eggs are 19-30 μm long by 10-20 μm wide 
(Sithithaworn and Haswell-Elkins 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I-4. Morphology of adult worms of a) Opisthorchis felineus and b) Opisthorchis viverrini 
(Figure reproduced from Bogitsh et al., 2013). 
 
For energy production the parasite uses glycolysis, yet, the glucose levels are 
reduced in bile (Masyuk et al., 2002). Therefore, the parasite evolved to adapt to a life 
there that allowed the degradation of free lipids and proteins to obtain energy (Young 
et al., 2014). 
a) b) 
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The Opisthorchis spp. have a complex life cycle involving two intermediates hosts, 
snails of genus Bithynia and cyprinid fishes, and definitive fish-eating mammals 
including cat, dogs, pigs, and accidentally, humans (Figure I-5) (Petney et al., 2013).  
 
 
Figure I-5. Developmental cycle of the liver flukes Opisthorchis viverrini and Opisthorchis 
felineus. Adult forms shed eggs that pass with bile into the small intestines, and then are excreted 
through feces. These eggs are ingested by snails in a situation where human waste from infected people 
is deposited into the freshwater environment. Following ingestion, the parasite's eggs hatch and 
miracidium undergoes through asexual reproduction that culminates in the release of cercariae into 
freshwater. The cercariae seek suitable species of fish of the family Cyprinidae where encyst. When 
mammals eat contaminated raw or undercooked fish, the metacercariae release the juvenile worm in 
the duodenum, which migrates until reaching the bile duct tree, where mature and produces eggs, 
completing the life cycle (Figure reproduced from Brindley et al., 2015). 
The eggs shed by adult worms are deposited in the biliary tree of the definitive host. 
Follow that, they reach the intestine with bile and are excreted through feces. Eggs 
Opisthorchis spp. adult 
worms in bile ducts 
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that reach water release the miracidia that are ingested by snails where undergoes 
through asexual reproduction to sporocysts, rediae, and cercariae for 4-5 weeks. Then, 
the cercariae are released into the water, seeks for fish and penetrate the skin between 
their scales. After a few days in the fish muscle, cercariae encyst as metacercariae, 
the infective form of the parasite. Animals and humans are infected through digestion 
of raw or undercooked fish (Kaewpitoon et al., 2008; Sripa et al., 2011), a common 
traditional practice in the countries where Opisthorchis spp. is endemic (Grundy-Warr 
et al., 2012). Following ingestion, metacercariae excyst in the duodenum and migrate 
through the ampulla of Vater into bile ducts of the liver, intrahepatic or extrahepatic 
ducts, where they mature into adult worms over a period of four weeks and start 
release eggs. In heavy infections, adult worms can also be found in gallbladder 
(Kaewpitoon et al., 2008; Sripa et al., 2010, 2011). The closely related liver fluke 
Opisthorchis felineus has a similar life cycle (Sripa et al., 2010).  
1.2.2. Historical review of opisthorchiasis 
The first description of parasites from Opisthorchis genus was performed by Rivolta 
in 1884 following the discovery of fluke in a cat liver from Nothern Italy. Initially, Rivolta 
(1884) classified the parasite as Distoma felineus. A few years later in 1891, a Russian 
scientist Vinogradov discovered this parasite in human and named it the “Siberian liver 
fluke”. Later, the parasite was renamed as Opisthorchis felineus which derived from 
Greek opisthen (behind) and orchis (testicles) (CDC, 2014). The parasite was firstly 
described in northern Thailand in 1911 during the autopsy examination of two prisoners 
(Leiper, 1915). Afterward, it was reported that 17% of 230 adult male prisoners 
examined in the same prison that Leiper conducted autopsy, were infected with was 
though to be O. felineus (Kerr, 1916). In 1927, a decade later, the worms were 
identified in young Thai male residing in the Northeast of Thailand (Prommas, 1927). 
During that decade, it was reported the finding of O. viverrini among Laotian people in 
Vientiane (15%) and Takhek (23%) (Bedier and Chesnau, 1929). A year after, the life 
cycle of O. felineus was described by german helminthologist Hans Vogel (Be’er, 2005). 
During the following decades of 50 and 60s, several researchers contribute to further 
knowledge of liver fluke infection in Thailand (Sadun, 1955; Harinasuta and Vajrasthira 
1962a, b; Wykoff et al., 1965). In 1955, Sadun stated that liver fluke infection observed 
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in Thailand was caused by O. viverrini, not by O. felineus, as first hypothesized, which 
was confirmed a decade later by Wykoff (1965).  
1.2.3. Opisthorchiasis: from geographical distribution to clinical presentation 
The term opisthorchiasis indicates two distinct infections: opisthorchiasis viverrini 
and opisthorchiasis felinea which are caused by O. viverrini and O. felineus, 
respectively. The geographical distribution of opisthorchiasis depends on two major 
factors: 1) the presence of the adequate intermediate hosts, snails, and fishes; and 2) 
consumption of raw or undercooked fish by local people (Sripa et al., 2011). The 
parasites have different geographical distribution which sometimes might overlap 
(Figure I.6).  
Usually, most of O. viverrini infections occur in countries bordering the Mekong 
River in Southeast Asia (Khuntikeo et al., 2018). Opisthorchiasis viverrini is highly 
prevalent in Thailand and Lao People’s Democratic Republic (PDR) affecting an 
estimate of 10 million people of these countries, but also occurs in Cambodia and 
Vietnam (Jongsuksuntigul and Imsomboon, 2003) (Figure I-6a). Recently, cases of 
opisthorchiasis viverrini in Myanmar have been reported (Aung et al., 2017).  
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Figure I-6. a) Global geographical distribution of Opisthorchis viverrini and Opisthorchis felineus 
infections. Occasionally, the geographical distribution of the two species overlapps (Figure reproduced 
from 
https://www.who.int/foodborne_trematode_infections/Distribution_of_opisthorchiasis_worldwide_1280
x876px.png. Last access on 6th August 2019); b) Distribution of Opisthorchis viverrini in Southeast 
Asia (Image reproduced from Khuntikeo et al., 2018); c) Prevalence of Opisthrochis felineus in 
Western Siberia which is higher than other part of Russia (Image reproduced from Pakharukova 
and Mordvinov, 2016). 
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In Thailand, the prevalence rate of infection differs in the four regions of the country 
with 80% of cases occurring in the North and Northeast regions (Figure I-6b) 
(Jongsuksuntigul and Imsomboon, 2003). In 2014, the prevalence rate had decrease 
leading to a corresponding decline in the national prevalence to 5.2% (Wongsaroj et 
al., 2014). Probably, this decrease occurred due to intensive and continuous control 
activities over the decades (Suwannatrai et al., 2018). Nevertheless, the prevalence of 
infection in many individuals’ providences within the North and Northeast and at the 
community level remains elevated (Wongsaroj et al., 2014; Suwannatrai et al., 2018). 
In Lao PDR the infection is widespread, and it is estimated that more than half 
population along Mekong River is infected (Rim et al., 2003; Parkin et al., 2006; 
Sayasone et al., 2007). The elevate prevalence is most likely related to the practice of 
consuming raw fish in communities in rural providence where up to 60% of fish carry 
infective form of parasite, metacercariae (Sayasone et al., 2007). On another hand, 
30% of domestic companion animals of those communities were infected with O. 
viverrini contributing to increase transmission of the parasites (Xayaseng et al., 2013). 
The number of cases of opisthorchiasis in Cambodia and Vietnam is unknown (Shin 
et al., 2010). 
The closely relative Opisthorchis felineus is highly endemic in Ukraine, Belarus, 
Kazakhstan, the Baltic countries and especially in Western Siberia where the 
percentage of infection varies from 10 to 45% (Figure I-6c) (Marcos et al., 2008; 
Pakharukova and Mordvinov, 2016). Of 17 million people infected with Opisthorchis 
flukes, it is estimated that 1.6 million are cases of opisthorchiasis felinea (Pakharukova 
and Mordvinov, 2016). In the European Union, human opisthorchiasis felinea was 
diagnosed more than 50 years ago in Germany, Greece, Lithuania, Poland, Romania 
and Spain (Erhardt, 1962). Nowadays, sporadic human infections have been 
documented in Germany and Greece (Sänger et al., 1991; Tselepatiotis et al., 2003). 
However, the parasite has been detected in red foxes, cats, dogs, fish and mollusks of 
several European countries as Germany, Poland, Portugal, Spain, Greece and Italy 
(Hering-Hagenbeck et al., 1996; Oliveira et al., 2005; Pozio et al., 2013). In the last 
years, outbreaks of human infection with O. felineus have been reported in Italy 
(Armignacco et al., 2008, 2013; Traverso et al., 2012; Pozio et al., 2013). From 2003 
to 2011, a total of 211 cases of human opisthorchiasis felinea have been confirmed in 
Italy (Pozio et al., 2013). The changes on food habits with increasing consumption of 
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raw marinated fish, among increase of travelers and/or migrants flow through endemic-
non endemic countries might turn opisthorchiasis felinea in an emerging parasitic 
disease in Europe (Pozio et al., 2013). 
1.2.3.1. Pathology and pathogenesis  
The infection caused by Opisthorchis spp. is associated with several hepatobiliary 
diseases (Mairiang and Mairiang, 2003; Yossepowitch et al., 2004). The pathological 
and clinical consequences of opisthorchiasis are related to the intensity and duration 
of infestations. Most of the infections caused by O. viverrini are asymptomatic. Usually, 
there is no acute phase, and only 5-10% of heavily infected individuals present mild 
symptoms like dyspepsia, abdominal pain, constipation or diarrhea (Upatham et al., 
1984; Mairiang and Mairiang, 2003; Kaewpitoon et al., 2008). During the chronic phase 
of infection, the symptoms can be more severe inducing several pathologic changes 
in liver, gall bladder, and extrahepatic bile ducts whereas parasite resides as adult form. 
For example, the biliary ducts might suffer a mechanical injury due to either feeding 
and migration of flukes, hook of oral and ventral suckers onto the biliary epithelial, 
release of metabolic products by parasite from tegument and excretory opening that 
come into contact with the bile duct epithelium. These metabolic products are thought 
to be immunogenic, mitogenic, and could be toxic. Consequently, their contact with 
biliary epithelium might origin cell desquamation, hyperplasia, periductal and periportal 
fibrosis, cholangitis, cholecystitis, and ultimately to the development of 
cholangiocarcinoma (CCA) (Sripa et al., 2007). Commonly, the liver and bile ducts of 
infected individuals are enlarged and dilated showing a prominent fibrotic wall 
(Hitanant et al., 1987; Riganti et al., 1988; Sripa, 2003), also subsequent cystic and 
saccular formations might occur (Harinasuta and Bunnang, 1990). Similar damage can 
occur to gallbladder which ultimately becomes unfunctional (Harinasuta and Bunnang, 
1990).  
Opisthorchiasis felinea is associated with a more pronounced and severe acute 
phase than opisthorchiasis viverrini. Acute opisthorchiasis felinea may be also 
asymptomatic, however, if the number of worms was significant symptoms as high-
grade fever, malaise, anorexia, diarrhea or constipation, arthralgia, lymphadenopathy, 
urticarial skin rash, dull pain and discomfort in the upper right quadrant of the abdomen 
are not infrequent. These symptoms may be associated with intermittent colic pain 
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caused by obstruction of the gallbladder by the worms. The chronic infection with O. 
felineus induced similar clinical manifestation and pathologies described for O. viverrini 
(Lvova et al., 2012; Maksimova et al., 2017). During this stage, it is commonly observed 
periductal fibrosis, destruction of the adjacent liver parenchyma, suppurative 
cholangitis, liver abscess, and granulomas (WHO, 1995b; Yossepowitch et al., 2004). 
Curiously, comparative studies of opisthorchiasis viverrini and felinea in a hamster 
model suggest that the histopathology of O. felineus infection might be more severe 
than of O. viverrini (Lvova et al., 2012). Also, O. felineus physiology, molecular biology, 
mechanism host-parasite interaction, and carcinogenic potential are less well studied 
than O. viverrini (Maksimova et al., 2017). 
1.2.3.2. Diagnosis of opisthorchiasis 
The gold standard for diagnosis of both opisthorchiasis is the fecal examination of 
the fluke egg’s (Sithithaworn et al., 1991; Upatham et al., 2003; Yossepowitch et al., 
2004; Sripa et al., 2011). The sensitivity and specificity of parasitological diagnosis rely 
on examination and experience of the microscopist. Moreover, in cases of light 
infection or bile duct obstruction, eggs may not be detected in the feces and might lead 
to a false negative result (Sithithaworn et al., 1991).  Thus, there is a need for a reliable 
diagnostic tool to overcome these issues (Yossepowitch et al., 2004). Several 
serologic/immunological tests for the diagnosis of opisthorchiasis including the 
intradermal test, immunoelectrophoresis, indirect haemagglutination assay, indirect 
fluorescent antibody test and indirect enzyme-linked immunoabsorbent assay (indirect 
ELISA) have been reported within greater sensitivity and specificity than fecal exams. 
The indirect ELISA is favoured for its ease and the increased sensitivity and specificity 
of diagnostic obtained by an antibody-based system (Srivatanakul et al., 1985; 
Thammapalerd et al., 1988; Sirisinha et al., 1991; Chaicumpa et al., 1992; Sirisinha et 
al., 1995; Watthanakulpanich et al., 1997; Wongsaroj et al., 2001; Waikagul et al., 
2002). Nevertheless, the complex composition of the crude antigen extracts and some 
cross-reactions with other parasitic infections might constitute a drawback of 
serological tests (Yossepowitch et al., 2004). More recently, molecular techniques as 
DNA hybridization and PCR-based methods have been investigated. However, further 
evaluations on their sensitivity and specificity are still required before its potential 
implementation (Wongratanacheewin et al., 2001, 2002; Ruangsittichai et al., 2006). 
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Despite the techniques mentioned above might be very effective for diagnosis of 
opisthorchiasis, so far, none of these methods replace the microscopic examination 
(Upatham et al., 2003). Imagiological tools as ultrasound, computed tomography or 
magnetic resonance imaging scans for diagnosis of advanced periductal fibrosis due 
to dilation and thickening from fibrotic deposition is already available (Mairiang et al., 
2006). 
1.2.4. Opisthorchis spp., major risk for development of cholangiocarcinoma 
Opisthorchis viverrini is also a definitive cause of cancer belonging to Group 1 
carcinogens (IARC, 1994). The correlation between the incidence of CCA and the high 
prevalence of opisthorchiasis viverrini was determined by epidemiological studies 
(Parkin, 2006; Shin et al., 2010). CCA is the most predominant type of liver cancer in 
Thailand (Sripa and Pairojkul, 2008), especially in the Northeast where the prevalence 
of infection is higher as mentioned above. Commonly, the first O. viverrini infection 
occurs in childhood which evolves into chronic infection in residents of endemic areas, 
and after three to four decades, the liver cancer is diagnosed (Sripa et al., 2011). CCA 
is a primary liver cancer-derived from cholangiocytes of the extrahepatic and 
intrahepatic bile ducts. This type of cancer is extremely invasive, develops rapidly, 
often metastasized, and has a very poor prognosis (Blechacz and Gores, 2008). 
Usually, it is asymptomatic during the initial phase and most of the times is diagnose 
in advance stage of cancer, thus, CCA is known as “silent killer” (Khuntikeo et al. 2018). 
The death of patients usually occurring within 3-6 months after diagnostic (Andrews et 
al., 2008). In northern Thailand, it is estimated that 5000 cases/year of CCA are 
diagnose (Parkin, 2006), which translates into 5000 deaths annually (Sripa et al., 2011). 
There is no medical treatment available, and surgery and supportive treatment are 
complicated due to the location of tumors, and often not accessible for patients in 
developing countries (Malhi and Gores, 2006).  
Unlike O. viverrini, its relative O. felineus do not belong to biological agent group 1, 
i.e. is not considered as carcinogenic, but is classified as potentially dangerous for 
humans (Group 3) (IARC, 2012). Until now, no association between O. felineus 
infection and CCA has been demonstrated. However, the prevalence of CCA in 
endemic areas of O. felineus in Western Siberia is three times higher than in another 
part of Russia (Sripa et al., 2007; Mordvinov et al., 2012). The role of parasite in the 
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development of CCA in humans remains elusive, probably due to the scarce of 
information regarding epidemiological and clinical programs for opisthorchiasis felinea 
(Pakharukova and Mordvinov, 2016). Nevertheless, the similarity of clinical 
manifestations and diseases caused by both parasites and the experimental data 
obtained through hamster model of infection opisthorchiasis felinea (Lvova et al., 2012; 
Maksimova et al., 2017) suggest that probably O. felineus also might have 
carcinogenic potential similarly to O. viverrini. Recent findings highlight the need for 
reconsideration the classification of IARC regarding infection with O. felineus (see 
Section III-Chapter 2). 
The mechanisms responsible for the onset of helminth-infection associated 
cancers remain unknown, and presumably, derived from a multifactorial process (Sripa 
and Pairojkul, 2007; Sripa et al., 2010). During the next chapter of this section, it will 
be discussed how and why helminths as S. haematobium and O. viverrini can induce 
cancer-associated to infection. 
 
2. Helminths and infection-associated cancer 
Infections are responsible for more than 20% of cancers in the developing world. 
The infections cause by several agents, mainly virus as Hepatitis B and C, human 
papillomavirus, Epstein Barr virus, and bacteria as Helicobacter pylori are widely 
known and recognized as biological cancers (Pagano et al., 2004; Bouvard et al., 2009; 
de Martel et al., 2012; IARC, 2012). Less appreciation has been given to helminth 
infections as a direct cause of malignancy. Since the early 1990s, infections caused 
by S. haematobium and O. viverrini have been recognized as the definitive cause of 
cancer and directly correlate with the development of SCC of the bladder and CCA, 
respectively (IARC, 1994, 2012). Interestingly, the chronic infection caused by other 
phylogenetic relatives of these parasites, e.g. Fasciola hepatica, has not been proven 
to be carcinogenic (Brindley et al., 2015). Why some helminths are causative agents 
of cancer? These differences may be related to several factors and/or a combination 
of thereof. Either the existence of specific helminth-metabolites contributing to 
tumorigenesis, exposure of tissues organs to parasite, and/or parasite-metabolites are 
particularly susceptible to infection-induced malignancy (Brindley and Loukas, 2017). 
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2.1. Risk factors leading to bladder cancer and cholangiocarcinoma 
associated to helminth infections 
Carcinogenesis is a complex process in which normal cell growth is modified as a 
result of the interaction of multiple factors (WHO, 2015). Several models have been 
proposed to explain the rise of cancer due to opisthorchiasis and UGS (Sithithaworn 
et al., 2012; Sripa et al., 2012; Honeycutt et al., 2014). 
In regions where opisthorchiasis is highly endemic the major risk factors for the 
development of CCA are either chronic inflammation and persistent parasitism that 
induce continuous damage of the biliary epithelium (Sripa et al., 2012; Blechacz et al., 
2011; Razumilava and Gores, 2013). Nonetheless, several other factors might be 
involved including increase of reactive oxygen and nitrogen species (ROS/RNS) or 
interleukin-6 (IL-6) among others factors derived from immune host attack directed 
against the worms (Jusakul et al., 2011), secretion by the parasite of mitogens such 
as granulin, thioredoxin and other mediators (Satarug et al., 1998; Sripa et al., 2012), 
dietary nitrosamines (Sripa et al., 2012), and others (Figure I-7). Additional to these 
factors, recently, liver fluke derived oxysterol-like metabolites that potentially damage 
host DNA have been related to carcinogenesis associated with opisthorchiasis (Vale 
et al., 2013).  
As for opisthorchiasis-associated CCA, several models for UGS-associated 
bladder cancer have been proposed over the years (Figure I-7) (Honeycutt et al., 
2014). Several factors including exposure to industrial and agriculture dyes, tobacco 
smoke, vitamin A deficiency, and exposure to low doses of nitrosamines are 
considered as potential carcinogenesis initiators in some models (Mostafa et al., 1999; 
Honeycutt et al., 2014). Recently, experimental studies using non-cancerous Chinese 
Hamster Ovary (CHO) cell lines exposed to secretions and lysates of S. haematobium 
eggs and adults worms stimulates cellular proliferation, migration, and invasion, 
inhibition of apoptosis, upregulation expression of Bcl-2 and facilitation of loss of p27 
(Botelho et al., 2009, 2011a, b) which are hallmarks of tumorigenesis and cancer cell 
survival (Hanahan and Weinberg, 2011). Recent studies using human epithelial cell 
lines (HCV29) co-cultured with S. haematobium eggs also demonstrated that the 
presence of eggs stimulates cell proliferation (Nacif-Pimenta et al., 2019). Moreover, 
in an animal model, intravesical administration to mice of S. haematobium antigens 
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and eggs induced urothelial dysplasia (Botelho et al., 2011b). This finding suggests 
that malignization of the bladder caused by S. haematobium infection is independent 
of the presence of nitrosamines (Botelho et al., 2011b). Among to these potential risks, 
catechol estrogens-like metabolites derived from S. haematobium might play an 
important role as chemical carcinogens in UGS-associated carcinogenesis (Correia da 
Costa et al., 2014; Brindley et al., 2015). Metabolites of estrogen have long been 
considered as carcinogenic chemicals and implied in several other cancers like breast, 
thyroid, prostate, non-Hodgkin lymphoma, among others (Cavalieri et al., 2002 and 
2006; Gaikwad et al., 2009; Zahid et al., 2013).  
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Figure I-7. Schematic representation of multifactorial processes that can contribute to the 
development of the biliary and bladder/urogenital tract cancers resulting from infection with the 
liver fluke O. viverrini and S. haematobium. On the left side of the diagram is depict the adult stage 
of O. viverrini and small bile ducts with cholangiocytes. On the right side of the diagram depicts the adult 
S. haematobium, and the urothelium lining the urinary bladder. Several factors may be related to the 
development of carcinogenesis associated with opisthorchiasis and UGS (Figure reproduced from 
Brindley et al., 2015). 
 
Estrogen and oxysterol-like metabolites within parasite origin might have a potential 
role in helminth infection-associated carcinogenesis. Which evidence associates these 
metabolites with infection caused by these helminths?  In the next subchapter, we will 
explore the evidence of estrogen and oxysterols-like metabolites associated with UGS 
and opisthorchiasis. 
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2.2. Evidences of parasitic catechol estrogens and oxysterol-like 
metabolites associated to helminth infection 
The first association of estrogen/estradiol to UGS occurred during the examination 
of human cases from Angola that presented elevated levels of estradiol in sera but not 
luteinizing hormone or testosterone (Botelho et al., 2009). Most likely, the elevation of 
estradiol observed was not related to human production of the hormone, but it could 
be attributed to schistosome production of estradiol-related metabolites (Botelho et al., 
2009). In fact, using liquid chromatography-mass spectrometry (LC-MS/MS) several  
estrogen-related metabolites including catechol estrogen quinones and catechol 
estrogen quinones-DNA adducts have been characterized in sera of UGS patients 
(Botelho et al., 2010, 2013) as well as in urine (see Section III-chapter 1) and 
developmental stages of parasites, including eggs (Botelho et al., 2013). The catechol 
estrogens detected (Botelho et al., 2010, 2013) are similar to those implicated on 
breast, thyroid and other cancers (Cavalieri et al., 1997, 2002, 2006) with hydroxylation 
and subsequent oxidation at positions C-2 and C-3 of the aromatic ring (Botelho et al., 
2013; Gouveia et al., 2013; Correia da Costa et al., 2014). The pathways and enzymes 
involved in the production of estrogen-like metabolites by schistosomes were predicted 
and reviewed by our research group  (Vale et al., 2017b, see Section VI-Appendix 1). 
This study is based on estrogen metabolism that is mediated by diverse cytochrome 
P450 enzymes (Vale et al., 2017b). The P450 metabolism of estrone and estradiol by 
17β-hydroxysteroid dehydrogenase generate 2-hydroxyestrogen and 4-
hydroxyestrogen (Cavalieri et al., 1997, 2002). Since schistosome genome encodes 
an ortholog of estradiol 17β-dehydrogenase that participates in the synthesis pathway 
of estradiol (Young et al., 2012), it is reasonable to speculate that parasite might exploit 
the production of estrogen-like metabolites during parasitic developmental stages 
(Correia da Costa et al., 2014; Vale et al, 2017b). The subsequent oxidation to catechol 
estrogen quinones might be performed by enzymes of P450 family as CYP1B1, 
CYP2E1 or CYP1A1 (Cavalieri et al., 1997, 2002). To a deeper understanding of how 
these metabolites and DNA adducts are formed, during this thesis, we performed in 
vitro studies to evaluate the influence of P450 enzymes in their formation (see Section 
III-Chapter 3).  
The catechol estrogens quinones detected (Botelho et al., 2010, 2013) might react 
directly with host DNA via Michael addition or indirectly via generation of reactive 
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oxygen species (ROS) leading to DNA damage either by forming apurinic sites or DNA 
oxidation (Cavalieri et al., 1997, 2002). As demonstrated in Section III – Chapter 1 of 
the present thesis, the evidence of DNA damage was detected in the urine of UGS 
patients. The catechol forms of estrogens can be inactivated through methylation 
mediated by catechol-O-methyltransferase (COMT), conjugation of the catechol 
estrogen quinones with glutathione-S-transferase (GSH), and enzymatic reduction 
(Cavalieri et al., 2002, 2006, 2011; Zahid et al., 2013). These processes prevent the 
accumulation of highly reactive metabolites. However, if they are insufficient, catechol 
estrogen quinones might accumulate and lead to DNA damage (Cavalieri et al., 1997, 
2002; Yager and Davidson, 2006; Cavalieri and Rogan, 2016). During UGS the activity 
of phase I and II drug-metabolizing enzymes in the urothelium of the bladder might be 
altered which interfere with the detoxification of xenobiotics and other homeostatic 
processes (Vale et al., 2017b). The GSH activity decreases during infection, and 
therefore, the highly reactive metabolites derived from parasite might accumulate in 
the urothelium of the bladder, and potentially increase the formation of DNA adducts. 
Indeed, DNA forms of catechol estrogen quinones were also detected in urine (Section 
III-Chapter 1) and sera of UGS patients (Botelho et al., 2010, 2013). Most likely, the 
formation of DNA adducts is a consequence of the interaction of parasitic metabolites 
with chromosomal DNA (Botelho et al., 2011, 2013). These evidences suggest that 
these reactive metabolites of estrogen might act as mutagens in UGS-induced bladder 
cancer (Correia da Costa et al., 2014; Brindley et al., 2015).    
Using the same technique, i.e. LC-MS/MS, estrogen and mostly oxysterols-like 
metabolites have been characterized in O. viverrini adult worms from experimentally 
infected hamsters. Several of structures are ramified at C-17 which means that 
presented discrete and variable chains linked to carbon 17 of the steroid ring (Vale et 
al., 2013). Oxysterols are products of oxidation of cholesterol either by P450 enzymes 
or non-enzymatic autoxidation processes (Jaworski et al., 2001; Jusakul et al., 2011). 
Interestingly, a sole member of the cytochrome P450 family of genes is known from 
the genome of Opisthorchis species (Pakharukova et al., 2012, 2015b; Ershov et al., 
2019). Presumably, the oxysterol-like metabolites from O. viverini might arise from 
non-enzymatic reactions with oxidative free radical-like oxygen and nitrogen species 
(Vale et al., 2013), but it is also reasonable to speculate that parasites might use P450 
ortholog for production of these metabolites. Like catechol-estrogens quinones, 
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oxysterols are potentially mutagenic, genotoxic and display pro-oxidative and pro-
inflammation activity that promotes and contribute at several stages of carcinogenesis 
(Kuver et al., 2012; Loilome et al., 2012; Jusakul et al., 2011, 2012). The association 
between different types of oxysterols and development of several cancers as colon, 
lung, breast, and bile ducts have been documented (Jaworski et al., 2001; Kloudova 
et al., 2017). The O. viverrini-infection is also commonly associated with elevation of 
bile acids, including deoxycholic acid (Vale et al., 2013), a potent tumor promoter in 
cholangiocarcinogenesis (Sirica, 2005). Bile acids constitute a large family of steroids 
containing a carboxyl group in the side chain, and bile alcohols have similar products 
in bile acid biosynthesis or as end products (Griffiths and Sjövall, 2010). Among 
oxysterols, bile acids, bile alcohols, and similar compounds but conjugated at different 
positions as bile aldehydes and bile sulfates, were also detected and characterized in 
extracts of O. viverrini adult worms (Vale et al., 2013). Probably, the effect of all these 
individual metabolites can be anticipated to be structure-dependent, and the 
occurrence of metabolic conversions can lead to the formation of a complex 
biologically of active or inactive forms (Vale et al., 2013). Opisthorchiids cannot 
synthesize cholesterol de novo, thus depending on the host to acquire this key nutrient 
(Young et al., 2014). Nevertheless, the liver flukes have evolved metabolic pathways 
highly adapted to a lipid-rich diet from bile and/or cholangiocytes (Young et al., 2012; 
Vale et al., 2013).    
A relation between oxysterol or bile acid-like metabolites from O. viverrini and CCA 
has been hypothesized since the early 1990s (Changbumrung et al., 1990). Recent 
studies performed in hamsters revealed that the oxysterols, cholestan-3β,5α,6β-triol, 
and 3-keto-cholest-4-ene, occur at elevated levels in the livers with O. viverrini-induced 
cholangiocarcinoma, and induce DNA adduct formation in cholangiocytes in vitro 
(Kuver et al., 2012; Jusakul et al., 2012). As with UGS, these reactive metabolites of 
cholesterol might be as the mutagens that contribute to liver-fluke infection-induced 
CCA (Vale et al., 2013). 
Although why and how these metabolites are acquired or synthesized by the 
parasites remain elusive, their formation might be related to the physiology of the 
worms and/or parasite-host interactions that modulate metabolic pathways of steroid 
hormones and bile acids (Brindley et al., 2015).  
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2.3. Oxysterols- and estrogen-like metabolites derived from helminth 
parasites as initiators of cancer? 
Cancer is a complex and heterogeneous set of diseases that involves distinct initial 
and sequential effects on the target cells: initiation, promotion, and progression 
(Anderson, 1971). The first involves damage to DNA, leading to mutations in one or 
more cellular genes that control key regulatory pathways of the somatic cell. An 
essential feature of promotion is the induction of proliferation in the initiated cells by 
continuous exposure to agents that are not necessarily carcinogenic (Brindley et al., 
2015). The progression results in further mutations from genetic instability during the 
promotion. Liver fluke-induced CCA and blood fluke-associated bladder cancer 
proceed through three essential steps, and otherwise display the ‘hallmarks of cancer’ 
(Mostafa et al., 1999; Honeycutt et al., 2014; Mesri et al., 2014).  
Oxysterols and catechol estrogens occur in both O. viverrini and S. haematobium 
(Botelho et al., 2010, 2013; Vale et al., 2013). Given that oxysterols and/or catechol 
estrogens of trematode origin and/or precursors might induce DNA damage (Figure 
I.8)  and mutate genes in other settings (Cavalieri et al., 2014), these metabolites might 
be considered as potential initiators of chemical carcinogenesis associated to 
opisthorchiasis and UGS (Correia da Costa et al., 2014; Brindley et al., 2015).  
 
Figure I.8. Metabolites excreted from parasites are highly reactive and might interact with host 
DNA leading to formation of DNA adducts. Probably this interaction triggers a cascade of events that 
ultimately culminate with development of infections-associated cancers. 
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Recently, a potential mechanism was postulated by our research involving helminth 
derived metabolites (reactive oxysterol and/or catechol estrogen derivatives) and their 
interaction with host DNA (Correia da Costa et al., 2014; Brindley et al., 2015). Briefly, 
both types of metabolites within parasitic origin are highly reactive and could react with 
host DNA yield DNA adducts that consequently induce lesions in chromosomes and 
promoted host cell DNA damage. The formation of DNA adducts induces continuous 
DNA oxidation and apurinic sites that eventually escape the DNA repair mechanism 
leading to mutations. The accumulation of mutations might transform the target cell 
originating hyperplasia and dysplasia, and also might induce dysregulation of 
oncogenes and tumor suppressors that ultimately culminate in the development of 
cancer (Figure I-9) (Correia da Costa et al., 2015; Brindley et al., 2015). 
 
Figure I-9. Postulated of chemical carcinogenesis mediated by oxysterols and estrogen-like 
metabolites derived from O. viverrini and S. haematobium. Metabolites derived from S. 
haematobium and O. viverrini might interact with chromosomes of target cells inducing DNA damage 
that eventually is not repaired and leads to the accumulation of mutations. This accumulation might 
transform the target cell leading to hyperplasia, dysplasia and, ultimately to carcinoma. (Figure 
reproduced from Correia da Costa et al., 2014) 
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As mentioned above, the accumulation of mutations could lead to a dysregulation 
of tumor suppressors. The overexpression and/or alteration of p53 during UGS have 
been described (Kidane et al., 2014; Santos et al., 2014) and might be related to the 
production of DNA adducts and oxidation of DNA. The p53 is a tumor suppressor 
protein involved in diverse pathways as a cellular response to DNA damage, initiation 
of DNA repair, among others (Habib et al., 2006; Nikoletopoulou et al., 2013). 
Dysregulation of the expression of the p53 gene may accelerate the tumorigenesis and 
alter the response of cellular agents that damage DNA (Colley et al., 2014). Studies 
performed using human epithelial lines (HCV29) co-culture with S. haematobium eggs 
and biopsies from the bladder of UGS patients from Angola demonstrated that p53 is 
usually altered during S. haematobium-infection (Warren et al., 1995; Santos et al., 
2014; Nacif-Pimenta et al., 2019). The dysregulation of p53 observed in the urothelium 
of the bladder associated with S. haematobium infection reinforce the notion that UGS 
alters the cellular process in this tissue and contribute to the development of bladder 
cancer due to continuous accumulation of mutations (Vale et al., 2017b). Tumor 
suppressor protein p53 is also a commonly mutated gene in Opisthorchis viverrini-
related CCA (Jusakul et al., 2015). 
 The oxysterol/estrogen-DNA adduct mediated pathway postulated (Correia da 
Costa et al., 2014; Brindley et al., 2015) is in line with the hypothesis recently proposed 
(Brücher and Jamall, 2014). According to the authors, a sequence of events must occur 
to originate cancer. First, it is necessary a biological or chemical stimulus, followed by 
chronic inflammation which leads to fibrosis, and a change in the tissue 
microenvironment. These alterations promote precancerous niche formation which 
triggers the deployment of the chronic stress escape strategy. If this strategy fails to 
resolve, the transformation of a normal into a cancer cell occurs originating cancer 
(Brücher and Jamall, 2014).  
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3. Current treatment and control for schistosomiasis and 
opishtorchiasis: a single drug 
The morbidity control of opisthorchiasis and schistosomiasis depends entirely on 
chemotherapy with a single drug, praziquantel (PZQ) (WHO, 2006). The pyrazino-
isoquinolone was developed in the 1970s through a collaboration between Merck and 
Bayern. Initially, PZQ was used for veterinary medicine as a broad-spectrum 
anthelmintic for companion animals and livestock (Andrews et al., 1983; Groll, 1984). 
In the late of 1970s and early 1980s, the drug was evaluated in a series of clinical trials 
against the major human schistosome species (Leopold et al., 1978; Davis and 
Wegner, 1979; Davis et al., 1979, 1981) followed by open-label clinical trials launched 
in Asia to assess its efficacy against members of Opisthorchiidae family (Bunnang and 
Harinasuta, 1981; Rim et al., 1981). For over more than 40 years and until today, PZQ 
is considered the ‘drug of choice’ for the treatment of human opisthorchiasis and all 
forms of schistosomiasis (Cioli and Pica-Mattocia, 2003; Olliaro et al., 2014). Since 
2006, PZQ has been extensively used in mass drug administration (MDA) programs in 
endemic regions as ‘preventive chemotherapy’ against these helminth diseases 
(WHO, 2006). Several millions of doses of PZQ have been consumed since 
implementation of MDA programs and it has been estimated that about 235 million 
people received PZQ until 2018, only for schistosomiasis (WHO, 2013). Nevertheless, 
regardless of the efforts of MDA programs to control liver and blood fluke infections, 
they remain a major public health concern (Andrews et al., 2008; Hughes et al., 2017). 
According to WHO, the recommended dose of PZQ for opisthorchiasis and 
schistosomiasis is 40 mg/kg at a single dose in preventive chemotherapy.  For 
opisthorchiasis, PZQ can also be administrated using three doses of 25 mg/kg daily 
for 2-3 consecutive days for individual treatment (WHO, 1995a). The administration of 
PZQ in patients with these helminthiases is well tolerated presenting only mild and 
transient adverse effects including abdominal pain, dizziness, nausea, vomiting, 
vertigo, headache, rash and hypotension (Haswell-Elkins and Levri, 2003). 
The major drawbacks of PZQ, mechanism of action and the potential emergence 
of resistance were extensively reviewed by Vale et al. (2017a, see Section VI-Appendix 
II). Briefly, the major shortcomings of PZQ include its inefficacy against juvenile forms 
including the schistosomula of Schistosoma spp. and Opisthorchis spp. newly 
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excysted metacercariae (NEM) (Pakharukova et al., 2015a; Vale et al., 2017a), has 
poor solubility and an extensive metabolism via hydroxylation of the absorbed drugs 
to inactive metabolites (Figure I.10) (Olliaro et al., 2014).  
 
Figure I.10. Metabolism of PZQ mediated by family of CYP450 enzymes. PZQ is a racemic mixture 
of enantiomers biologically active (R-PZQ) and inactive (S-PZQ) isomers. The drug is metabolized by 
CYP450 resulting in 4-OH-PZQ as the main product and other minor enantiomers as cis- or trans-4-OH-
PZQ. Bold green and blue arrows indicate major metabolites of PZQ enantiomers. (Figure adapted from 
Vale et al., 2017a).  
Although administration of PZQ might clear the infection, alone the drug cannot 
prevent or ameliorate inflammation, fibrosis-related to the infection and re-infection. 
Therefore, PZQ cannot counteract the risk factor for the development of cancer 
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associated with these infections (Hughes et al., 2017). Interestingly, some studies in a 
hamster model of O. viverrini infection reported that repeated infection and 
consequence PZQ re-treatment can increase the risk of CCA due to augment of 
inflammatory cells which increase oxidative and nitrative stresses and apoptosis 
(Pinlaor et al., 2004, 2009a). Nonetheless, no conclusive evidence correlates the PZQ-
repeated treatment with CCA in human cases (Kamsa-ard et al., 2013). 
Regardless of its wide usage, the mechanism of action of PZQ is unknown (also 
reviewed by Vale et al., 2017a). Nevertheless, it has been postulated that PZQ disrupts 
ion calcium (Ca2+) homeostasis but how the drug alters it remains unclear (Valle et al., 
2003; Greenberg, 2005). The hypothesis that PZQ alters Ca2+ channels is supported 
by finding of studies that employed calcium channels blockers and cytochalasin D 
(Troiani et al., 2007). PZQ might be a G-protein-coupled receptor ligand, with PZQ 
acting as an agonist at the human 5-HT2B receptor (Chan et al., 2013). The drug 
causes immobilization, spasmodic contractions, paralysis of the worm accompanied 
by tegument damage (Angelluci et al., 2007; Tallina and Redi, 2007), as evidence of 
extensive swelling, erosin, vacuolisation and peeling (Pakharukova et al., 2015a). The 
pathological vacuolization of the tegument cells causes leakage of sugars and amino 
acids and cell lysis leading to the death of parasite (Angelluci et al., 2007; Chan et al., 
2013).  
Due to reliance of single drug for these two major helminth infections spread 
worldwide, there is a growing and legitimate concern that resistance to PZQ might 
evolve (Doenhoff et al., 2008; Merrifield et al., 2016; Trainor-Moss and Mutapi, 2016). 
Thus far, PZQ resistance is not of clinical concern, however, field and experimental 
isolates, especially for schistosomes, exhibiting significantly reduced susceptibility or 
low cure rates have been described, foreboding the emergence of drug resistance in 
these parasites (Fallon, 1998; Wang et al., 2012). Unlike reported for schistosomiasis, 
so far, there is no evidence of opisthorchiids resistance to PZQ. Nevertheless, it is 
plausible to presume that due to its massive and extensive use, the PZQ-resistance 
and/or decrease susceptibility of liver flukes to the drug will emerge. 
Based on these facts, the search for additional or alternative drugs against 
Opisthorchis and Schistosoma species has become a public health priority. Curiously, 
the research for alternative therapies against opisthorchiids has attracted much less 
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attention than for schistosome. Very little research on this topic is conducted outside 
of Thailand and Russia.  
 
 
4. Alternative therapeutic approaches against schistosomiasis and 
opisthorchiasis  
Over the past years, extensive efforts been made through the synthesis of derivates 
of PZQ and evaluation of anthelmintic activity either in vitro or in vivo (Doenhoff et al., 
2008; Liu et al., 2012). Unfortunately, these derivatives did not present better activity 
in comparison to the parent drug (Vale et al., 2017a). Therefore, there is a reawakening 
of the need to search for alternatives to PZQ. Strategies as the development of 
combinations of PZQ with drugs or other active agents (Keiser et al., 2011) and drug 
repurposing (Panic et al., 2014; Cowan and Keiser, 2015) might constitute promising 
and efficient tools against these helminthiases (Panic et al., 2014).  
4.1. Drug repurposing and combination of drugs 
The concept of drug repurposing is based on the identification of new therapeutic 
indication for already approved or investigational drugs that are outside of the initial 
purpose (Ashburn and Thor, 2004). This is a useful strategy that offers several 
advantages to accelerate the drug development process due to lower cost, reduce risk, 
and decreased time to availability of preclinical data (Padhy and Gupta, 2011). On the 
other hand, rational combination therapy consists of the use of one or more drugs or a 
combination of drugs with other active agents. Initially, the rational combination of 
chemotherapy was developed for tuberculosis and other bacterial infection (Kerantzas 
and Jacobs, 2017). Nowadays, its use has been extended for chemotherapy of cancer, 
acquired immune deficiency syndrome (AIDS) (Maenza and Flexneer, 1998), and for 
malaria (Nosten and Brasseur, 2002; Wells et al., 2015). The major goals of 
combination chemotherapy are minimized or delay the potential arises of resistance 
(Maenza and Flexner, 1998; Wells et al., 2015; Kerantzas and Jacobs, 2017), and/or 
achieve additive/synergistic effect that could be translated in reduced doses of drugs 
along with the reduction of adverse effects (Kerantzas and Jacobs, 2017).  
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The state of the art regarding drug repurposing and combination of drugs, as well 
the use of antioxidants either alone or combine with PZQ and other drugs against 
schistosomiasis, were extensively reviewed by Gouveia et al. (2018; see Section VI-
Appendix 3). Here presents a brief summary of the studies described in our review.  
Several classes of pharmacological agents including anthelmintics, antimalarials, 
anti-inflammatory, contraceptives agents, have been evaluated and suggested for drug 
repurposing against schistosomiasis. The drugs including artemisinin´s derivates (e.g. 
artesunate (AS) and artemether (ART)) and mefloquine (MFQ) which are widely 
acknowledged for their antimalarial activity (Ashley and White, 2005) have been 
demonstrated an interesting antischistosomal activity. These compounds are highly 
active against juvenile’s worms (Ashley and White, 2005) whereas PZQ is only 
effective against adult worms. Thus, antimalarials counteract one of major shortcoming 
of PZQ. Over the years, antimalarials were tested either alone or combined with PZQ 
and evaluated not only in the laboratory but also in clinical trials where achieved 
promising results against schistosomiasis (De Clercq et al., 2000; Borrmann et al., 
2001; Mamhoud and Botros, 2005; Hou et al., 2008; Inyang-Etoh et al., 2009; Keiser 
et al., 2009a; Xiao et al., 2009, 2011; Yunusa et al., 2016). Due to their different mode 
of action, the combination of artemisinin´s derivatives and PZQ should lead to the 
elimination of parasites in larval form and adult worm which might be very useful in 
regions with an elevated rate of re-infections. A recent meta-analysis confirms that 
antimalarials as artemisinin derivatives used in combination with PZQ exhibited the 
increased cure rates in schistosomiasis treatment. Also, suggest that repeated doses 
of artemisinin derivatives might play a prophylactic role due to its activity against the 
larvae stage of schistosomes (Pérez del Villar et al., 2012). MFQ is considered one of 
the best antischistosomal drugs being active not only against larvae but also adult 
schistosomes. This antimalarial drug display better antischistosomal activity in 
comparison to artemisinin derivatives and PZQ. Additionally, MFQ combine with AS 
exhibit higher cure rates against schistosomiasis mansoni and UGS (Xiao, 2013). 
Other pharmacological agents including anti-inflammatory, ibuprofen and naproxen, 
antifibrotic, lipid lowering agents as atorvastatin, and synthetic lipids, edelfosine, were 
also being evaluated against schistosomiasis. Although the anti-inflammatory agents 
do not exhibit antischistosomal activity per se, they played a role in amelioration of 
inflammation, biochemical and histopathological consequences related to intensity of 
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infection, and decrease in granuloma diameter (Mahmoud et al., 2002). Similarly, 
antifibrotic agents as β-aminopropionitrile-monofumarate salt and β-aminopropionitrile 
combined with PZQ reduced sizes of granulomas and alleviate the host resistance to 
challenge infection. The administration of combine regimens of these drugs with PZQ 
lead to absence of worm recovery and only dead ova were observed. The results 
achieved by combine regimens were better than monotherapies alone (Giboda et al., 
1992; Hassan et al., 2003). Combine lipid lowering agent and injectable contraceptive 
medroxyprogesterone acetate result in severe tegumental damage and significantly 
decrease the total number of S. haematobium worms recovered from infected 
hamsters. Intriguingly, female worms were less susceptible to either drugs alone or 
combine in comparison to males (Soliman and Ibrahim, 2005). Unlike PZQ, edelfosine, 
a synthetic lipid, presented antischistosomal activity against larvae and adult stage of 
S. mansoni. Apparently, the antischistosomal activity of this synthetic lipid depend on 
its action on the tegumental structure (Yepes et al., 2014). In addition, combined 
regimens of edelfosine plus PZQ in vivo not only eliminated the schistosomes 
developmental stages but also improve histopathological parameters as reduced 
granuloma size and hepatomegaly. Furthermore, it potentiated anti-inflammatory 
actions and favor resistance to re-infection render eldefosine a promising candidate for 
a prophylactic treatment of schistosomiasis (Yepes et al., 2015).  
The paucity of alternatives against opisthorchiasis might relate to a  certain delay 
in the studies into the systematic biology of opisthorchiids resulting from a relatively 
lower abundance of the corresponding helminthiases as compared with 
schistosomiasis. Consequently, insufficient research attention towards this problem. 
Similarities between the morphology, anatomic structure and physiological process 
typical of trematodes suggest that the label extension and drug repurposing can also 
be successfully applied to the development of opisthorchicidal drugs (Mordvinov and 
Furman, 2010). A few interesting candidates for drug repurposing and drug 
combinations against opisthorchiasis have studied over the past years. Below is briefly 
present the most promising drugs and its effects against either opisthorchiids or 
pathologies associated with infection.  
During the 1980s, the potential opisthorchidal activity of drugs albendazole (ABZ) 
and mebendazole (MBZ), was evaluated in laboratory studies (e.g. in vitro and in vivo) 
and clinical trials. These drugs have been widely and effectively used in the treatment 
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and control of soil-transmitted nematode infections (Utzinger and Keiser, 2004). The 
administration of drugs to opisthorchiasis patients twice daily for 3-4 days only 
achieved moderate cure rates, albeit with egg reduction rates above 90% (Pungpark 
et al., 1984). Treatment with MBZ was also effective in eliminate opisthorchiasis 
presenting low toxicity (Jaroonvesama et al., 1981). In a recent clinical trial, 
administration of ABZ eliminate the O. viverrini infection in children co-infected with 
nematodes, and was more effective than MBZ (Soukhathammavong et al., 2012). 
Recently, a novel complex of ABZ with polysaccharide arabinogalactan demonstrated 
to be highly effective against O. felineus in vitro presenting an anthelmintic activity at 
significantly lower doses than ABZ, and also showed lower acute toxicity and 
hepatotoxicity than the parent compound (Chistyachenko et al., 2015). Since 
antimalarials shown potent activity against schistosomes, they may also have potential 
for treatment and control of opisthorchiasis. Semi-synthetic derivatives as artemether 
(ART) and artesunate (AS) were administered to O. viverrini-infected hamsters which 
result in worm burden reduction between 60-80%. Even at higher dose (600 mg/kg), 
the complete elimination of the parasite was not achieved and both drugs showed toxic 
effects (Keiser et al., 2006). In a similar fashion to artemisinin´s, the appealing 
antischistosomal activity of mefloquine (MFQ) triggered interest in its possible activity 
against opisthorchiasis. In a similar fashion to observed against schistosomes, MFQ 
achieved better opisthorchidal activity than AS and ART either in vitro and in vivo. A 
single oral dose of MFQ resulted in high worm burden reductions not only against 
juvenile but also adult O. viverrini (Keiser et al., 2009b). The MFQ induces severe 
tegumental alterations including sloughing, furrowing and bebbling following incubation 
in vitro, suggesting that drug targets the fluke´s tegument (Keiser et al., 2009b). 
Tribendimine (TBD), was initially developed in an attempt to control tapeworm and 
threadworm infections in China (Xiao et al., 2005). Laboratory and clinical 
investigations demonstrated the therapeutic safety of TBD (Xiao et al., 2005). The in 
vitro assays demonstrated that exposure of parasites to TBD at lower drug 
concentrations lead to its rapid contraction and consequently to death. Administration 
of a single oral dose of TBD in vivo resulted in high worm burden reduction. Similar to 
MFQ, TBD induces severe tegumental disruption as sloughing, furrowing, and bebbling. 
Also, TBD damage the oral sucker of parasite leading to a complete closure of the 
mouth of the liver fluke, however, the O. viverrini recovered from infected hamsters 
remain alive in contrast to observed in vitro. Its impressive activity in vitro even at lower 
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concentrations only translated to a moderate worm burden reduction in vivo (Keiser et 
al., 2008). Nevertheless, opisthorchidal activity of TBD was evaluated in two 
randomised, parallel-group, single-blind, dose-ranging, phase 2 trials in children, 
adults and adolescent were performed in three O. viverrini-endemic villages in 
southern Laos (Sayasone et al., 2016). Several doses of TBD were evaluated in 
different ratios according to age of the children. The aim of these trial was to estimate 
the dose-response relations in terms of cure rate and egg reduction rate. The results 
obtained demonstrated that TBD has excellent efficacy and tolerability at doses of 100 
mg/kg and above. Nonetheless, it should be note it that mainly adults and children 
presented low-intensity O. viverrini infection, thus, further studies including patients 
with moderate and high intensity are warranted (Sayasone et al., 2016). In a recent 
clinical trial whose aim was to compare the efficacy of administration of a single oral 
dose of TBD with two oral doses of PZQ demonstrated that TBD has a slightly lower 
cure rate than PZQ. Nevertheless, TBD has a similar egg reduction rate to PZQ and 
leads to fewer adverse events (Sayasone et al., 2018). The opisthorchidical effect of 
combination of PZQ with TBD was also evaluated either in vitro and in vivo. While in 
vitro the combination presented a synergistic effect, when both drugs were 
administered in vivo simultaneously or on subsequent days achieved low to moderate 
worm burden reduction, suggesting antagonistic effects (Keiser et al., 2008). It remains 
unclear why this apparent contradiction occurs but could be related to 
pharmacokinetics or pharmacodynamic drug interactions in vivo (Sayasone et al., 
2016). Through the analysis in vitro of anthelmintic activity of various CYP inhibitors 
against juvenile and adult O. felineus, miconazole (MCZ) and clotrimazole (CTZ) were 
the most effective reducing CYP activity but also decreased the viability of the liver 
flukes (Mordvinov et al., 2017). The inhibition of CYP activity might be relevant since 
parasite encodes a CYP enzyme active on parasite tissues that could be essential for 
its survival (Pakharukova et al., 2015b). The activity of these two agents, both 
approved by the United States Food and Drug Administration, was comparable to that 
for PZQ (Mordvinov et al., 2017). The combination of CTZ or MCZ with PZQ also lead 
to contradictory results. Similar findings to those were seen for TBD (Keiser et al., 
2013). The synergistic effect of the PZQ+CTZ and PZQ+MCZ observed in vitro, 
unfortunately were not evident in vivo (Mordvinov et al., 2017). The low efficacy of 
these azoles agents could be attributed to low drug concentration in the hepatobiliary 
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system where parasites reside. Repetitive dosing at constant time intervals may 
maintain appropriate drug levels in the hepatobiliary system (Pakharukova et al., 2018).  
4.2. Antioxidant biomolecules: a promising alternative? 
As mentioned in Chapter 2, it has been postulated that Opisthorchis spp. and S. 
haematobium produces/excrete metabolites that might be considered as potential 
initiators of infection-associated carcinogenesis (Correia da Costa et al., 2014; Brindley 
et al., 2015). Ideally, the treatment for opisthorchiasis and schistosomiasis not only 
should target the elimination of the parasites but also ameliorate and prevent 
pathologies associated to the infections. In our point of view, the novel therapeutic 
alternative should inhibit the formation of potentially carcinogenic metabolites that 
ultimately might counteract the initiation of carcinogenesis. It has been demonstrated 
that antioxidants as resveratrol (Resv) and N-acetylcysteine (NAC) can block cancer-
initiating process associated to breast and other cancers by counteracting the 
production of carcinogenic metabolites (Zahid et al., 2008, 2010, 2011). Antioxidants 
are considered pharmacologically safe agents presenting minimal side effects 
(Ratman et al., 2006; Sindhi et al., 2013), and might prevent DNA damage (Pinlaor et 
al., 2009b), stimulate some important antioxidant enzymes that regulate the elimination 
of reactive electrophilic compounds (Soliman et al., 2008) and present and/or enhance 
anthelmintic activity (Sayed et al., 2008; Seif-el-Din et al., 2011). Therefore, the 
biological properties of antioxidants biomolecules either alone or combined with drugs 
might offer a major contribution to therapeutic against these helminth infections in 
amelioration of associated pathologies and perhaps, ultimately counteract initiation of 
carcinogenesis. 
Biological and natural agents as antioxidant biomolecules have attracted interest 
against schistosomiasis and opisthorchiasis. Indeed, the use of antioxidants either 
alone or combine with different class of drugs have been achieve promising results 
(reviewed in Gouveia et al., 2018, Section VI-Appendix 3). However, clinical trials to 
assess the inclusion of antioxidants in therapy against these helminth infections have 
yet to be launched.  
Several antioxidants assessed have shown potential antischistosomal activity 
either in vitro and in vivo not only against mature (Rojo-Arreola et al., 2014; Rizk et al., 
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2012; Mata-Santos et al., 2010; Eraky et al., 2016) as well as in immature forms of 
schistosomes (Mantawy et al., 2012; Oliveira et al. 2014; Eraky et al., 2016;). 
Evidences point out that some antioxidants affect the motor activity of the worms in 
vitro suggesting a possible perturbation/dysfunction of neuromuscular system (Oliveira 
et al., 2012). The neuromuscular systems are a crucial element for schistosomes since 
they control not only movement, but also oral and ventral suckers involved with 
parasites attachment. In addition, they support internal organs including the 
reproductive, excretory and digestive tracts, and maintenance of the female with the 
gynecophoral canal of the male (Ribeiro and Patocka, 2013; Patocka et al., 2014). Also, 
antioxidants also target the parasite tegument (Oliveira et al., 2012; Rizk et al., 2012; 
Eraky et al., 2016) which is a crucial organ for protection against host responses, 
nutrient uptake for parasite development and growth (De Paula et al., 2016). Besides 
the antischistosomal activity, it has been demonstrated that antioxidants are capable 
to restore the activity of antioxidant liver enzymes (El-Ansary et al., 2007; Rojo-Arreola 
et al., 2014; Soliman et al., 2017), which is usually accompanied by reduction on 
granuloma size and number resulting in improvement of liver architecture and functions 
(Rojo-Arreloa et al., 2014; Kamel et al., 2015; De Paula et al., 2016). Another 
interesting aspect of antioxidants is that they could modulate and immunomodulatory 
response, promoting alteration in some cytokines (El-Shennawy et al., 2007; Wan et 
al., 2017) that might be also helpful to reduced size and number of granulomata. 
Generally, administration of antioxidants concomitantly with antischistosomal drugs 
improves not only parasitological but also biochemical parameters (Mahmoud et al., 
2002; El-Lakkany et al., 2012; Ebeid et al., 2014). Similar effects of antioxidants have 
been observed against opisthorchiasis. A few antioxidants agent as melatonin (MEL) 
(Laothong et al., 2010, 2013; Wongsena et al., 2018), curcumin (Curc) (Pinlaor et al., 
2009b, 2010; Charoensuk et al., 2011, 2016), xanthohumol (XTH) (Jamnongkan et al., 
2018) and plant extracts (Drab et al., 2005; Wonkchalee et al., 2013) were evaluated 
and achieved informative results not only in elimination of parasites, but also in 
remission of infection and carcinogenesis. Antioxidants derived from plant extracts 
exhibits high anti-O. felineus in vivo activity exceeding PZQ efficiency. After treatment 
no eggs were recovered suggesting that compound might block egg production (Drab 
et al., 2005). By the other hand, antioxidants as Mel, Curc or XTH diminished the DNA 
lesions through reduction of oxidative and nitrative DNA damage in the nucleus of the 
bile duct epithelium, suppress the inflammatory responses (Laothong et al., 2010 and 
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2013; Pinlaor et al., 2009), reduce status changes including iron accumulation, 
periductal fibrosis, and even suppress development of CCA in experimentally rodent 
model of opisthorchiasis viverrini and administration of N-dinitrosomethylamine 
(NDMA) in hamsters. (Wonkchalee et al., 2013; Jamnongkan et al., 2018). These 
ameliorations increase the survival of animals (Laothong et al., 2010, 2013). 
Apparently, antioxidants might exert a chemopreventive effect against liver injury and 
CCA, at least in the hamster model (Laothong et al., 2010, 2013; Wongsena et al., 
2018). Antioxidants as XTH may repress CCA development via antioxidant activity 
through protection of cholangiocytes from oxidative stress (Jamnongkan et al., 2018). 
Generally, combination of these antioxidants with PZQ improve the histopathological 
features mentioned above (Pinlaor et al., 2010; Wonkchalee et al., 2013; Charoensuk 
et al., 2016).  
Considering the studies mentioned above, combination among different agents 
with PZQ or other anthelmintic drugs might be a possibility to overcome limitations of 
PZQ. Additionally, the administration of antioxidants in rodent models of these helminth 
infection ameliorate the infection-associated pathologies and enhance antioxidant and 
immunological responses. Notably, the use of antioxidants followed by treatment with 
PZQ can lead to suppression of CCA. Studies related to the effect of antioxidant 
against UGS-associated cancer are scarce. This could be related to the difficulty of 1) 
maintain life cycle in laboratory and 2) establish a reliable animal model of UGS-
associated SCC. The combined treatment might present a dual therapeutic effect and 
could be related to their different modes of action and/or act on different targets. Thus, 
strategies as drug repurposing and combination of drugs with antioxidant agents 
should be pursued. 
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II. AIMS OF THESIS 
1. Aims of doctoral thesis 
The present thesis focused on two main aims.  
1) First, contribute to an understanding of the potential role of metabolites derived from 
helminths as S. haematobium and Opisthorchis spp. in the infection-associated 
carcinogenesis. The specific aims within this topic were:  
a) provide insights into carcinogenesis of UGS-induced bladder cancer.  
Are metabolites present urine of UGS-patients similar to those observed in serum from 
UGS patients? Is there evidence of detectable DNA in the urine of these patients? If 
these metabolites promote DNA damage, we should be able to detect molecular signs 
of chromosomal lesions, as DNA-adducts and the presence of 8-oxodG (Section III-
Chapter 1); 
b) Understand why infection with only a few helminths induce cancer.  
By contrast to O. viverrini, its closely relative O. felineus is not considered carcinogenic 
(IARC, 2012). Some evidence suggests that this classification is due to the lack of 
epidemiological studies (Pakharukova and Mordvinov, 2016). Thus, we performed 
some biochemical and histopathological studies using hamsters experimentally 
infected to assess O. felineus carcinogenic potential. (Section III-Chapter 2). Does O. 
felineus also produce/excrete metabolites similar to those detected in O. viverrini? Is 
there evidence of interaction of these metabolites with host DNA? Does O. felineus 
infection induce cancer?; 
c) comprehend how these metabolites derived from parasites could be formed.  
Will the estrogen metabolism associated enzymes (P450 family) be important for its 
formation? Or can they be formed through non-enzymatic processes?  (Section III- 
Chapter 3). 
2) The second principal aim was to develop a novel therapeutic approach that not only 
targets the parasite but also could improve pathologies associated with infection and 
ultimately prevent carcinogenesis. As mentioned in the previous section, control and 
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treatment for these helminth diseases rely on a single drug, PZQ, that targets the 
parasite rather than the pathological conditions caused by its infection including cancer 
(Vale et al., 2017). Considering that metabolites produced/excreted by parasites play 
an important role in the development of cancer associated with infection, it is important 
to develop a new therapeutic strategy that potentially counteracts their formation. Thus, 
based on the concepts of drug replacement and/or combination, we propose a novel 
therapeutic strategy which consists of the combination of different classes of drugs 
(anthelmintic, antimalarial and anticancer) with antioxidant biomolecules that might 
present dual mode of action (Figure II-1). 
 
Figure II-1. Novel therapeutic approach and desire effects against opisthorchiasis and 
schistosomiasis.  
 
Regarding the development of the novel therapeutic strategy, the specific aims 
were to evaluate its effect on i) elimination of developmental stages, i.e. larva (Section 
III-Chapters 4 and 5) and adult worms (Section III-Chapter 6) of S. mansoni. Due to 
difficulty of S. haematobium grow in rodent and therefore is challenging to maintain its 
life cycle in the laboratory (Keiser, 2010) the evaluation of novel therapeutic approach 
was performed in S. mansoni model which life cycle is well established in Centro de 
Saúde Pública Dr. Gonçalves Ferreira-Instituto Nacional de Saúde Dr. Ricardo Jorge-
Porto (INSA-Porto) Laboratories. Are antioxidants capable of enhancing the activity of 
drugs? Do antioxidants themselves exhibit anthelmintic activity?; ii) and inhibiting the 
formation of parasite-derived metabolites. Can the novel therapeutic strategy inhibit 
the formation of these potentially carcinogenic metabolites? (Section III-Chapter 7). 
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CHAPTER 1. Estrogen-like metabolites and DNA-adducts in urogenital schistosomiasis-
associated bladder cancer. 
 
Authors: Maria João Gouveia, Júlios Santos, Paul J. Brindley, Gabriel Rinaldi, Carlos 
Lopes, Lúcio L. Santos, José Manuel Correia da Costa, Nuno Vale. 
 
The paper presented in this Chapter had the main aim provide an understanding of 
carcinogenesis associated with Schistosoma haematobium infection. Based on results 
obtained in cell lines and animal model, previously, our research group postulated an 
estrogen-DNA adduct mediated pathway that may be involved in pathogenesis of 
bladder cancer associated with Schistosoma haematobium infection. During this work 
we search for scientific evidence in humans that supports our postulate which 
attributes a high relevance role to estrogen metabolites in the molecular mechanisms 
implicated in UGS-associated carcinogenesis. For that purpose, biological samples 
(urine and bladder mucosa tissue) were collected from a group of patients with UGS 
from Angola, properly characterized from the clinical, histopathological and 
epidemiological point of view. Urine samples were analyzed using the Liquid 
Chromatography coupled to Mass Spectrometry (LC-MS/MS). The results 
demonstrated notable differences among the groups of participants. Furthermore, it 
demonstrated the presence of specific estrogen metabolites excreted in the urine of 
patients with UGS but not identified in a urinary metabolite database of healthy humans. 
These metabolites were identified as catechol estrogen quinones (CEQ) and CEQ-
DNA adducts (molecules resulting from the interaction of CEQ with host DNA) which 
some of them had been identified previously on developmental stages of parasite. 
Additionally, novel metabolites derived directly from 8-oxo-7,8-dihydro-2'-
deoxyguanosine (8-oxodG), an indicator molecule for DNA damage, were identified in 
urine of all UGS cases. These metabolites can be expected to provide deeper insights 
into the carcinogenesis UGS-induced bladder cancer, and as biomarkers for diagnosis 
and/or prognosis of this neglected tropical disease-linked cancer. 
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The liver fluke Opisthorchis felineus is a member of the triade of epidemiologically 
relevant species of the trematode family Opisthorchiidae. Unlike Opisthorchis viverrini, 
group 1 agents and a major risk factor for cholangiocarcinoma, the carcinogenic 
potential of the infection with O. felineus is less clear. In this research we investigate if 
1) Opisthorchis felineus also presented oxysterol-like metabolites similar to those 
detected in O. viverrini and 2) carcinogenic potential of the infection with O. felineus. 
To that we conducted both biochemical and histopathological investigations in hamster 
experimentally infected with O. felineus, a widely studied model of human 
opisthorchiasis and liver fluke infection-induced hepatobiliary disease as 
cholangiocarcinoma (CCA). The findings presented in this chapter support the 
inclusion of O. felineus in the Group 1 list of biological carcinogens. Two discrete lines 
of evidences emphasize the notion that O. felineus infection is carcinogenic. On one 
hand, novel oxysterol-like metabolites detected by LC-MS/MS in the egg and adult 
developmental stages of parasite, and in biological samples (bile, urine and sera) of 
liver fluke-infected hamsters exhibited marked similarity to oxysterol-like molecules 
known to O. viverrini. On other hand, histopathological analysis of liver sections from 
hamster infected with O. felineus revealed inflammation, severe periductal fibrosis and 
changes in the epithelium of biliary tract characterized as biliary intraepithelial 
neoplasia (BilIN), an established precancerous lesion that precedes intrahepatic CCA. 
The consonance of these findings revealed that O. felineus infection in rodent model 
induced precancerous lesions conducive to malignancy. 
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induces the formation of DNA-adducts 
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Infections classified as group 1 biological carcinogens include the helminthiases 
caused by Schistosoma haematobium and Opisthorchis viverrini. As presented in 
previous chapters, we have postulated that these parasites release metabolites 
including oxysterol and estrogen-like metabolites that might interact with host DNA. 
During the work presented in this Chapter we evaluate the role of CYP450 in the 
formation of metabolites associated with helminth infections and its interactions with 
DNA. For that purpose, we performed in vitro assays using similar compounds to 
parasitic metabolites reported, and exogenous DNA in the presence or absence of 
CYP1A1, 2E1 and 3A4. The reaction products identified by LC-MS/MS shown the 
formation of similar metabolites previously associated with schistosomiasis and 
opisthorchiasis and DNA-adducts proving its ability to interact with DNA. Apparently, 
CYP450 was not essential for the formation of these metabolites. The formation of 
DNA adducts in vitro supports the hypothesis that chemical carcinogenesis might be 
involved in promoting helminthiases-associated carcinogenesis. 
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The antioxidants resveratrol and N-acetylcysteine enhance anthelmintic activity of 
praziquantel and artesunate against Schistosoma mansoni. 
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The main purpose of this research work was evaluated the efficacy our novel 
therapeutic approach against newly transformed schistosomula (NTS). We used a 
host-parasite model involving Bioamphalaria glabrata and Schistosoma mansoni to 
established mechanical transformation of S. mansoni cercariae into NTS and 
optimized their culture conditions. Thereafter, we investigate the antischistosomal 
activity and ability of antioxidants as N-acetylcysteine (NAC) and resveratrol (Resv) to 
enhance the performance of praziquantel (PZQ) and/or artesunate (AS) against larval 
stage of the parasite. The efficacy of drugs either alone or combined was evaluated 
either by using an automated microscopical system and by transmission electron 
microscopy (TEM). The results obtained demonstrated that combination of PZQ+Resv 
and AS+Resv displayed synergy. In consonance to these results, TEM observations 
demonstrated that combination of AS+Resv induced severe, extensive alterations to 
the tegument and subtegument of NTS when compared to the compounds alone. The 
synergies observed might be the consequence of increased action by Resv on targets 
of AS and PZQ and/or they might act concomitantly on discrete targets to enhance 
overall antischistosomal action.  
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The research work presented in Chapter 5 consisted in a follow-up of that 
presented in previous chapter. In this study we used the same host-parasite model for 
in vitro drug screenings assays. Here, we selected different classes of drugs 
(anthelmintic and anticancer) and several antioxidants and evaluated either alone or 
combined. The morphological alterations induced by compounds alone or combined 
were assessed on daily basis using an inverted and automated microscope combine 
with a flurometric-based method to quantify NTS viability. The findings indicate that not 
only do some antioxidants improve antischistosomal activity of drugs, but also 
exhibited activity per se (e.g. Curc and 4-phenyl-1,2,5-oxadiazole-3-carbonile-2-oxide 
(OXA) and Curc) leading to high mortality of NTS post-exposure. The combination 
index (CI) for several combinations anthelmintic+antioxidant (e.g. PZQ+Mel, 
PZQ+Resv, AS+Resv, AS+NAC) and anticancer+antioxidant (e.g. VDT+Flavone 
(Flav), VDT+Resv) reveal that display moderate to strong synergism. Repurposing of 
drugs as anticancer (or others) seems to be worthwhile since they were affective 
against larval stage. We consider that this approach might be valuable for use in 
regions with intense re-infection levels since the combination might block or retard 
parasite infection and development. 
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The purpose of research work presented in this Chapter was evaluated the novel 
therapeutic approach against adult worms of S. mansoni. During this research work 
we investigate the antischistosomal activity of anthelmintic, anticancer drugs and 
antioxidants alone and combined. For that purpose, the adult worms were recovered 
from experimentally infected mice by perfusion of portal veins and used for in vitro 
antischistosomal activity assay as described during this Chapter. Additionally, the 
effect of drugs and antioxidants either alone or combine on oviposition was also 
evaluated. Similarly, to observed for NTS, antioxidant biomolecules by itself presented 
an interesting antischistosomal activity and also enhance antischistosomal activity 
against adult worms. Interestingly, anticancer drugs also induce high mortality of adult 
worms in vitro. Most of the drugs evaluated as some antioxidants cease the oviposition 
of adult worms either by its death or possible damage in reproduction apparatus of 
female. Taken together these results, the concepts of drug repurposing and 
combination of agent with different mode of action might be relevant to prevent 
sequelae associated to infection since eggs are one of the major factors for 
inflammatory processes associated to helminth infection. 
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Abstract  
Despite the efforts to control and eliminate schistosomiasis, this neglected tropical 
disease remains a major public health problem. Currently, the treatment for 
schistosomiasis relies on a single drug, praziquantel (PZQ). Although PZQ is effective 
against the adult worms, its present major drawbacks including inefficacy against the 
juvenile and alone is not capable to counteract infection-associated disease lesions 
including hepatic fibrosis. Moreover, there is a legitimate concern about the emergence 
of PZQ-resistance. Therefore, there is a pressing need for novel therapies that not only 
target parasite but prevent or decrease infection-associated pathologies. Antioxidants 
present interesting biological properties that might render them a valuable tool for 
schistosomiasis. Previously, we observed synergistic/additive effect through the 
combination of drugs and antioxidants against newly transformed schistosomula (NTS) 
of Schistosoma mansoni. Here, we investigated this novel therapy approach against 
adult worms of S. mansoni. The findings indicate that some antioxidants showed 
antischistosomal activity per se against adult worms, and slightly improve the 
antischistosomal activity of drugs when combined. Additionally, the novel therapeutic 
approach prevents oviposition which could be crucial to counteract the pathologies 
associated with infection. Eggs released from parasites are directly linked to the 
formation of granuloma and inflammation associated with parasitic infection. Therefore, 
these evidences could be important since the manipulation of the rate of oviposition 
might eventually lead to new approaches for disease control. 
 
Keywords: Schistosoma mansoni, adult worms, antioxidant biomolecules, drug 
repurposing, combination therapy, oviposition. 
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1. Introduction 
Schistosomiasis is one of the most important neglected tropical diseases. The 
infectious agents are helminth parasites of genus Schistosoma (WHO, 2012), and 
three main Schistosoma species including Schistosoma mansoni, S. haematobium 
and S. japonicum, are responsible for human schistosomiasis. Only S. haematobium 
is considered carcinogenic and responsible for about 90% of infections in Africa Sub-
Sahara and (WHO, 2012). Schistosomiasis is one of the most widespread parasitic 
infection with high levels of incidence in Asia, Africa and Latin America affecting 207 
million people and about 779 million are at risk of infection (WHO, 2012). Recently, 
outbreaks of schistosomiasis haematobia have been reported in Western Europe 
(Berry et al., 2014; Boissier et al., 2016). 
For over more than 40 years, the control and treatment of schistosomiasis rely on 
a single drug, praziquantel (PZQ) (Vale et al., 2017). Despite its efficacy against all 
forms of human schistosomiasis and low toxicity, the drug has major drawbacks as a 
limited effect on juvenile schistosomes and on liver a spleen lesion as a consequence 
of infection and liberation of eggs by adult worms (Sabah et al., 1986). Moreover, due 
to the extensive and long-term repeated use of PZQ, there is a growing and legitimate 
concern about the development of drug resistance or reduced susceptibility (Vale et 
al., 2017). Thus, there is a consensus on the urgent need to develop novel, affordable 
and effective therapies against this debilitating parasitic disease. Drug repurposing 
and/or combination of distinct biological active agent might be an efficient approach to 
reduce time and cost of drug research and development (Keiser et al., 2011; Cowan 
and Keiser, 2015). The current therapy for schistosomiasis mainly targets the parasite 
and not the pathologies associated with the infection (Vale et al., 2017). During the 
host immune response to the presence of the parasite occur the liberation of reactive 
oxygen species (ROS) which might disturb the cellular antioxidant homeostasis of 
affected organs (Maizels et al., 1993; Gharib et al., 1999). Regard to S. haematobium 
infection our research group suggested that reactive electrophilic compounds, e. g. 
estrogen-like metabolites might act as potential initiators of infection-associated 
bladder cancer (Costa et al., 2014; Brindley et al., 2015). From our perspective, novel 
therapeutic approaches should focus not only on the elimination of the parasite but 
also ameliorate the pathologies associated with the infection.  
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We speculate that a novel therapeutic approach based on drug repurposing and a 
combination of different active agent might be a valuable tool not only to eliminate the 
parasite but also ameliorate the infection-associated pathologies. The antioxidants 
presented interesting and promising biological properties. Antioxidants are considered 
pharmacological safe agents (Ratman et al., 2006; Sindhi et al., 2013) and might 
prevent DNA damage (Allam, 2009), block carcinogenesis (Zahid et al., 2001), and 
present antischistosomal activity by themselves (Gouveia et al., 2018 and 2019a and 
b). These properties render them as interesting candidates for use against 
schistosomiasis. Therefore, we propose a novel therapeutic approach based on drug 
repurposing and a combination of a different class of drugs (anthelmintic and 
anticancer) with antioxidants (Figure 1). 
This novel therapeutic approach was previously evaluated on newly developed 
schistosomula (NTS) of S. mansoni (Gouveia et al, 2019). Here, we undertook its 
evaluation against adult worms of S. mansoni and its effect on oviposition. 
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Figure 1. Structures of anthelmintic, anticancer drugs and antioxidant biomolecules evaluated either 
alone or combined against S. mansoni adult worms. The anthelmintic drugs are depicted at blue, 
anticancer drugs in red and antioxidant biomolecules in green. 
 
2. Material and methods 
2.1. Chemicals and culture media 
Praziquantel (PZQ), 4-phenyl-1,2,5-oxadiazole-3-carbonile-2-oxide (OXA), N-
acetylcysteine (NAC), flavona (Flav), flubendazole (FBZ) were purchase from Merck 
Sigma-Aldrich (Lisboa, Sigma), and resveratrol (Resv) from Santa Cruz Biotechnology 
(Heidelberg, Germany), artesunate (AS), vandetanib (VDT), curcumin (Curc), and 
melatonin (Mel) from Cayman Chemical (Ann Arbor, MI, USA) and the dipeptide H-L-
tryptophan-L-serine-OH (H-Trp-Ser-OH, DiPept) from Bachem (Bubendorf, 
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Switzerland). The culture media RPMI 1640 and supplements as penicillin (10,000 
U/mL)/streptomycin (10 mg/mL) from Merck Sigma-Aldrich and heat inactivated fetal 
bovine serum (iFBs) from Lonza (Basel, Switzerland). For in vitro assays, stock 
solutions of (2-5 mg/mL) were freshly prepared in 100% dimethylsulfoxide (DMSO) 
(Sigma-Aldrich) and stored at 4ºC. These stock solutions were then diluted in fresh 
culture media before its addition to the well containing adult worms. 
2.2. Parasites 
The life cycle of the S. mansoni strain is maintained by passage through 
Bioamphalaria glabrata snails and CD1 mice obtained from Center for Vector and 
Infectious Disease Studies Francisco Cambournac and maintained at animal facility of 
Public Health Care Dr. Gonçalves Ferreira (INSA-Porto). Female mice CD1 (8 weeks 
old) were infected with 160-180 cercariae using tail immersion technique (Oliver and 
Stirewalt, 1952) and after 7-8 weeks days of infection, S. mansoni adult worms were 
recovered under aseptic conditions by perfusion of the livers and mesenteric veins 
(Smithers and Terry, 1965). The worms were washed in RPMI 1640 medium (Merck 
Sigma-Aldrich), supplemented with 1% penicillin/streptomycin and 10% bovine fetal 
serum (iFBS). The experiments were conducted in accordance with the law DL 
113/2013 of Portuguese Republic and European Directive 2010/63/UE and were 
approved by the Ethics of Animal Experiments of INSA-Porto (project no. 04/2018) and 
Directorate General Food and Veterinary. 
2.3. In vitro antischistosomal activity 
The procedure to evaluate the antischistosomal activity of compounds alone or 
combined against adult worms was similar to those previously described (Cowan and 
Keiser, 2015). Briefly, one adult coupled S. mansoni worm pair (one female and male) 
in RPMI 1640 medium (1 ml) were placed in each 48-well plates (Nunclon, Denmark). 
The screening of test compounds was performed at a concentration of 100 μM and 
combination at a constant ratio (1:1) at same concentration. All the compounds were 
prepared as described above and added to RPMI 1640 medium containing the worms 
after a period of 24h to recover from the eventual stress of perfusion and adaptation to 
culture medium. The parasites were kept for 72h in a constant temperature incubator 
at 37ºC in an atmosphere of 5% CO2 and monitored 1, 17, 24, 48 and 72h for motor 
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activity, mortality and morphological alterations as described elsewhere (Lombardo et 
al., 2018; Cowan and Keiser, 2015). Adult worms incubated with the highest 
concentration of DMSO (0.1%) served as negative control. Phenotypic changes were 
recorded using a light microscope (Nikon Phase Contrast 2, LDW 0.52, Japan). Briefly, 
the morphological alterations were scored ranging from 0 to 3 (0= all worms dead, 1= 
minimal activity (severe reduction in motility), severe morphological/tegumental 
changes, 2= slowed activity (reduced motility, first morphological/tegumental changes, 
and 3= totally vital, normal active, no morphological changes) (Manneck et al., 2010). 
Adult worms were considered dead when no movement was observed for at least 2 
minutes (Manneck et al., 2010). The percentage of effect was calculated using a 
previously described equation (1) (Lombardo et al., 2018). All experiments were 
carried out in duplicate and repeated at least one time. 
 
% 𝐸𝑓𝑓𝑒𝑐𝑡 = 100 −
(𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑡𝑒𝑠𝑡)∗100
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
  (Eq. 1) 
 
2.4. Statistical analysis 
The mean and standard deviation were calculated using GraphPad Prism 6 
(GraphPad Software, Inc). 
 
3. Results and Discussion 
Novel therapeutic approach that not only eliminate the parasite but also could 
improve and ameliorate the pathologies associated to infection is required against 
schistosomiasis (Gouveia et al., 2018). Repurposing and combination of drugs with 
active compounds with a different mode of action might be an effective strategy 
(Cowan and Keiser, 2015). We hypothesized that combining drugs with antioxidants 
could enhance not only the efficacy of the drug to eliminate the parasite, but also could 
improve/prevent sequelae associate with infection (Gouveia et al., 2018). Previously, 
we evaluate different classes of drugs and antioxidants either alone or combined 
against newly transformed schistosomula (NTS) of S. mansoni and observed that most 
of the combinations were more active rather than drugs and antioxidant alone (Gouveia 
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et al., 2019a and b). Herein, we evaluated the efficacy of our novel therapeutic strategy 
against adult worms of S. mansoni in vitro.  
3.1. Repurposed drugs and its combination with antioxidants presented 
interesting antischistosomal activity  
As depicted in Figure 2 and Supplementary Figure S1 (see Section VI-Appendix 5), 
the worms of the control group (RPMI 1640 with 0.1% DMSO) remain viable and 
without morphological alterations followed 72h post-exposure. Regard to anthelmintic 
drugs alone, the most active was PZQ with an effect of 86.7% on males and 50.0% on 
females. PZQ induced the death of male following 24h of exposure while female 
remains alive but with several morphological alterations after 72h (Supplementary 
Figure S1 and Figure 2). These results are in consonance with those described in the 
literature reporting that males are more susceptible to PZQ than females (Vale et al., 
2017). In contrast, the males were less susceptible to AS than females as described 
elsewhere (Utzinger et al., 2007) which were dead follow 48h of exposure. In fact, the 
effect of AS (20.0% for female and 0.0% for male) was lower than PZQ (Figure 2). 
Nevertheless, we observed that AS induced the decoupling at 48h of exposure and 
dead of female at 72h of exposure (Supplementary Figure S1 and Figure 2). Regard 
to the activity of PZQ and AS against NTS, PZQ induced severe morphological 
alterations on NTS, yet, most of the larvae remain alive following 72h of exposure while 
AS induce the death of most larvae (Gouveia et al., 2019a and b). The data obtained 
for these drugs is in accordance to literature where it is reported that AS is more active 
against juvenile forms while PZQ is more active against adult worms (Utzinger et al., 
2007). The other anthelmintic drug evaluated, FBZ, has been reported that in mice 
reduce the number of adult parasites of S. mansoni (Nessim et al., 2000), however, in 
this study FBZ had no effect (0.0%, Figure 2) on morphology of males which remained 
vital and active (Supplementary Figure S1). The female worm seems to be more 
susceptible to drug presenting slight morphological changes (Figure 2 and 
Supplementary Figure S1). FBZ is more active against NTS than adult worms even 
more active than AS or PZQ (Gouveia et al., 2019b). This finding suggested that this 
repurposed drug is more suitable for administration on the initial stage of infection.  
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Figure 2. Score viability and graphical representation of percentage of effect (numbers above columns) 
induced by drugs and antioxidant alone or combined (1:1) at 100 μM against adult worms of S. mansoni 
in vitro. (M-males and F-females). 
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In general, the antischistosomal activity of anticancer drugs were more pronounce 
against adult worms than anthelmintic drugs evaluated. From anticancer drugs 
evaluated TMT was more active (68%), followed by VDT (60.0% for males and 30.0% 
for females) and IMT (48.0%) (Figure 2). Except for IMT, VDT and TMT induced the 
dead of both parasites after 48h post-exposure (Figure 2). Regard to worms incubated 
with VDT was also detectable differences between the sensitivity of male and female 
(60.0% vs 30.0%), with males being more susceptible than females (Figure 2). IMT 
caused severe morphological alterations but not the death of parasites (Figure 2), 
however, lead to a decoupling of worms following 17h post-exposure. Curiously, 
anticancer drugs also presented an interesting antischistosomal activity against NTS 
(Gouveia et al., 2019b) counteracting one of the major drawbacks of PZQ. These 
anticancer drugs are kinases inhibitors and kinases play a pivotal role for different 
physiological processes namely reproduction and egg production (Grevelding et al., 
2018). Most likely, the antischistosomal activity observed could derive from potential 
inhibition of these enzymes on parasites.  
Of antioxidant evaluated, OXA and Curc were highly active leading to the death of 
both parasites following 17h of exposure which translated in a percentage of effect 
above 90.0% (Figure 2). OXA and Curc were more active than PZQ itself (Figure 2) 
like observed against NTS (Gouveia et al., 2019b). Despite the mechanism of action 
of these two antioxidants are uncertain, some reports attributed activity of OXA to the 
fact that it could inhibit thioredoxin glutathione reductase (TGR) which is essential for 
parasite survival (Sayed et al., 2008) while Curc probably could be involved in parasite 
biochemical processes as ubiquitin-proteasome pathway (Chen et al., 2012). Regard 
to other antioxidants evaluated, Resv, NAC, DiPept and Mel, did not shown any 
antischistosomal activity against adult worms similarly to observed for NTS (Gouveia 
et al., 2019b). The parasites incubate with these antioxidants remained viable without 
any significant morphological alterations during the assay (Figure 2 and 
Supplementary Figure S1). Intriguingly, Resv displays a moderate antischistosomal 
activity (Gouveia 2019b) against NTS while only slight morphological alterations were 
observed against adult worms (Figure 2 and Supplementary Figure S1) mainly on the 
females. On the other hand, Flav had a minimal effect (16.0%, Figure 2) causing slight 
morphological alterations (Figure 2) but not the death of parasites. In these cases, no 
differences in susceptibilities between males and females were observed. By contrast, 
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Flav presents moderate antischistosomal activity against NTS (Gouveia et al., 2019b). 
The mode of action for these two antioxidants remain unknown, however, has been 
hypothesized that Resv could act on neuromotor activity (Gouveia et al., 2019a and b) 
while Flav could modulate key cellular enzyme functions (Panache et al., 2016). 
Further studies are required to understand which the targets of antioxidants and drugs 
on adult forms of S. mansoni are.  
Herein, we evaluated if combining antioxidant with drugs enhance their 
antischistosomal activity. The antischistosomal effect in the combination of drugs with 
antioxidants was identical to those induced by drugs (e.g. TMT+Mel or TMT+Flav) or 
antioxidants alone (e.g. AS+OXA and AS+Curc) (Figure 2). Nevertheless, the 
antischistosomal activity observed in combinations as AS+NAC, AS+DiPept, AS+Flav, 
AS+Mel, IMT+Flav, FBZ+Flav or Mel, VDT+Resv or Flav, was slightly better than drugs 
alone (Figure 2). The enhancement of the antischistosomal activity of IMT+Flav and 
VDT+Resv was more pronounced especially against females (Figure 2). While the 
combination of VDT+Flav induces a percentage of effect of 86.7%, the drug alone has 
an effect of 60% for male and 30% for female (Figure 2).  
On the other hand, combinations as PZQ+Resv and AS+Resv apparently act as an 
antagonist, especially against males. The male's worms incubated with these 
combinations presented a better viability score than those with drug alone. This 
translate into a higher percentage of effect of drug alone rather than combinations 
(Figure 2). Interesting, these combinations against NTS were classified as synergistic 
(Gouveia et al., 2019). These findings could suggest that the combination of the mode 
of action of PZQ or AS with Resv could be more effective and suitable for NTS than 
adult worms. Presumably, these combinations are more suitable for the initial stage of 
infection rather than chronic infection where worms are already fully developed. By 
contrast, combinations as FBZ+Flav, IMT+Mel or AS+Mel that act as slightly or 
antagonistic against NTS (Gouveia et al., 2019b), here, enhance the antischistosomal 
effect in comparison to compounds alone (Figure 2). This reinforces the notion that 
development stages of parasites have different susceptibilities which suggest that 
targets are different on NTS and adult worms.  
Additionally, the combination of antioxidant and antioxidant was also assessed 
against adult worms. The antioxidants that presented slight or no antischistosomal 
activity when evaluated alone were combined (Figure 2). In general, these 
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combinations did not improve their antischistosomal activity, most of them had 0.0% 
of the antischistosomal effect (Figure 2). Nevertheless, NAC, DiPept, and Mel 
combined with Flav display a moderate activity (33.0%, Figure 2) especially against 
males (e.g. Flav+NAC and Flav+DiPept). These combinations slightly improved the 
activity of Flav alone (33.0% vs 16.0%, Figure 2). Similarly, the two antioxidants more 
active (i.e. Curc and OXA) when combined slightly increase their antischistosomal 
activity against adult worms (Figure 2). 
3.2. Oviposition is highly affected after exposure of parasites to antioxidants 
either alone or in combination with drugs 
The pathologies associated with chronic schistosomiasis occurs mainly due to egg 
deposition that triggers an inflammatory reaction leading to the formation of granuloma 
in organs where parasite reside (Hussein et al., 2012). The egg production not only 
induces pathologies-associated to the infection but is also an indicator of worm viability. 
Thus, oviposition could be an important target for the development of novel 
approaches for schistosomiasis (Badr et al., 1999). The reproductive capacity of 
parasites is based on two major criteria: pairing and egg production. The first indicate 
if the mating process occurs and the latter is an indicator of egg output (Veras et al., 
2012). Although some compounds alone or combine did not induce the death of 
parasites, they could prevent oviposition which could be crucial to counteract the 
pathologies associated with infection [(Supplementary Table S1, see Section VI-
Appendix 5) and Figure 3]. All drugs evaluated against adult worms ceased oviposition 
either by inducing their death (e.g. PZQ) or by decoupling (e.g. AS). Interestingly, FBZ 
did not induce severe morphological alterations or decoupling, however, leads to a 
cessation of the oviposition suggesting that the reproductive system of the female was 
affected. Indeed, the percentage of antischistosomal effect of FBZ was more 
pronounced in females rather than males (Figure 2).  
Regard to antioxidants OXA, Curc, Flav, and Resv alone also cease the oviposition 
(Figure 3). In the case of OXA and Curc, this occurs due to the death of parasites. On 
the other hand, like FBZ, Flav and Resv did not induce severe morphological 
alterations or dead of parasites (Figure 2), however, they cease the oviposition (Figure 
3). The mechanism of action of these antioxidants remains elusive. Nevertheless, 
based on these findings it is reasonable hypothesized that might be related to the 
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degenerative process of the female apparatus, at least in vitro. In contrast, the other 
antioxidants evaluated (DiPept, NAC) did not affect oviposition nor morphological 
alterations (Figure 2 and 3) reinforcing that they do not present any antischistosomal 
activity. However, all combinations of drugs with antioxidants also leads to the 
cessation of oviposition in a similar fashion to observed with compounds alone. 
Therefore, it is reasonable hypothesized that it could be related to the activity of drugs 
or antioxidant alone (i.e. Flav and OXA) and not the combination itself.   
In combinations of antioxidant and antioxidant, the cessation of oviposition only 
occurs when Flav was combined with other antioxidants (Figure 3), thus, this might be 
related to the antischistosomal activity of Flav. The other combinations evaluated (e.g. 
Mel+DiPept, Mel+NAC or NAC+DiPept) did not affect the oviposition. As mentioned 
above these antioxidants did not induce any morphological alterations which are in 
consonance to the fact that parasites continue producing eggs during the assay.  
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Figure 3. Effect of drugs and antioxidants alone or combine on oviposition. The points represented the 
number of eggs observed per pair incubated with compounds alone or combine during the assay in vitro.  
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4. Conclusion 
To conclude, we report the effect of the different class of drugs and antioxidant 
biomolecules alone or combine against adult worms of S. mansoni. Not only some 
antioxidants alone (e.g. OXA and Curc) were highly active against adult worms, but 
also some combinations (e.g. drugs plus antioxidant or antioxidant plus antioxidant) 
enhance antischistosomal activity against adult worms. The increase of 
antischistosomal activity might be related to their different mode of action and/or 
targets on adult’s worms. Since eggs are one of the major factors for inflammatory 
processes related to the parasitic infection (Hussein et al., 2012), and implicated on 
development of bladder cancer in infection with S. haematobium (Brindley et al., 2015), 
it might be relevant cease the oviposition. Indeed, the combination of different active 
agents evaluated during this study achieve the cessation of the oviposition, at least in 
vitro.  Taken together with the previous results with NTS (Gouveia et al., 2019b) and 
against adult worms, repurposing of drugs as anticancer (or others) might be 
worthwhile since they were effective against all developmental stages of S. mansoni 
(Gouveia et al., 2019b). Also, due to their biological properties of antioxidants in 
prevention of DNA damage and blocking cancer initiation process (Allam, 2009; Zhaid 
et al., 2001), they could play a pivotal role in amelioration of sequelae associated to 
infection (Gouveia et al., 2018) and even counteract carcinogenesis during infection 
with helminth parasites, namely S. haematobium (Correia da Costa et al., 2014; 
Brindley et al., 2015) through cessation of oviposition or by prevent the formation of 
potential parasitic metabolites implicated in carcinogenesis associated to 
schistosomiasis haematobia. Future studies are required to evaluate these 
combinations either in vivo in laboratory rodent models and cells lines to understand 
their effect on amelioration of sequelae and cancer induced by infection of 
Schistosoma species. 
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Supplementary information (see Section VI – Appendix 5) 
Table S1. Oviposition expressed as the mean of number of eggs deposited per worm 
during in vitro assay. 
Figure S1. Representative micrographs of adult worms following 72h of exposure to 
anthelmintic [praziquantel (PZQ), artesunate (AS), flubendazole (FBZ)], anticancer 
drugs [imatinib (IMT), trametinib (TMT) and vandetanib (VDT)], antioxidants [(4-phenyl-
1,2,5-oxadiazole-3-carbonile,2-oxide (OXA), N-acetylcysteine (NAC), resveratrol 
(Resv), flavone (Flav), H-Trp-Ser-OH (DiPept), melatonin (Mel)] alone and combined 
(1:1) at 100 μM.  
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CHAPTER 7. Inhibition of the formation in vitro of putatively carcinogenic metabolites 
derived from S. haematobium and O. viverrini by combination of drugs with 
antioxidants 
 
Authors: Maria João Gouveia, Verónica Nogueira, Bruno Araújo, Fátima Gärtner, and 
Nuno Vale 
 
During the research paper presented in this Chapter we evaluate the efficacy of a 
novel therapeutic strategy to prevent the formation of putative carcinogenic metabolites 
precursors and DNA adducts. Using the same methodology described on chapter 4, 
we synthesized metabolites and DNA adduct from starting compounds glycocholic acid 
and taurochenodeoxycholate sodium in presence of CYP450 in vitro. The products of 
reaction were identified and characterized by liquid chromatography coupled to mass 
spectrometer (LC-MS/MS). The next phase consisted in evaluating the inhibition of 
their formation induced by drugs and antioxidants alone or combined in vitro. For that, 
we incubate the starting compounds, DNA, CYP450, drugs (e.g. AS and PZQ) and 
antioxidants (e.g. NAC and Resv) either alone or combined and analysed by LC-
MS/MS followed 72h of reaction. Drugs and resveratrol alone did not present a 
significant inhibitory effect while N-acetylcysteine inhibited the formation of most 
metabolite precursors and DNA adducts. The inhibitory effect of drugs seems to be 
affected by CYP450. This could be counteracted by combine drugs with agent that 
modulate CYP450 activity as Resv. Indeed, the combinations of drugs plus 
antioxidants were more effective rather compounds alone, especially AS+Resv which 
inhibit most of metabolites and DNA adducts. Therefore, the therapeutic strategy might 
be a valuable tool to prevent initiation of helminth infection-associated carcinogenesis. 
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IV. Discussion  
 
1. General discussion  
More than 20% of cancers in developing countries are caused by infectious agents. 
Among these agents are Schistosoma haematobium and Opisthorchis viverrini that 
are considered carcinogenic (IARC, 2012). In endemic areas, epidemiological studies 
related their infection with development of squamous cell carcinoma (SCC) of bladder 
and CCA, respectively. However, the molecular/cellular mechanism linking these 
infections with cancer remain elusive. What is the role of helminths in infection-
associated carcinogenesis? The carcinogenesis is multistep and multifactorial process 
(Sripa et al., 2010; Honeycutt et al., 2014), but it is plausible assume that helminths 
have a role in development of associated cancers either their interaction host-parasite 
and/or production of metabolites that are putatively carcinogenic. It has been 
postulated that estrogen and/or oxysterol-like metabolites in form of catechol derived 
from helminths and DNA adducts have been implicated, at least in part, as initiators of 
carcinogenesis promoted by these parasites (Correia da Costa et al., 2014; Brindley 
et al., 2015).  
In order to provide deeper insights of UGS-associated cancer, 40 urine from 
Angolans with UGS, half of who also presented UGS-associated SCC and/or urothelial 
cell carcinoma were analysed by LC-MS/MS (Section III-Chapter 1). The analysis 
revealed the presence of numerous estrogen metabolites in the urine of the study 
participants which seven of these molecules were specifically identified in UGS cases 
but notably were not described in the recently reported metabolome of urine from 
healthy humans (Bouatra et al., 2013). The schistosome infection-associated 
metabolites included catechol estrogen quinones that are potentially reactive with host 
DNA. Indeed, evidence of this interaction were also observed supported by the 
presence of DNA adducts in urine. Additionally, evidence of DNA oxidation was also 
detected in the form of molecules derived from 8-oxodG, a major chromosomal lesion 
caused by DNA oxidation (Salim et al., 2008; Na et al., 2011). The presence of 
derivatives from 8-oxodG in the urine of individuals with UGS, supports the notion that 
metabolites of estrogen derived from schistosome might induce lesions in host cell 
chromosomes (Botelho et al., 2011). Previously, indicators of oxidative stress were 
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already detected in soluble lysates of the adult developmental stages of S. 
haematobium (Botelho et al., 2010, 2013), and this mechanism is likely involved in 
induction of SCC during UGS (Salim et al., 2008). Indeed, there is increasing evidence 
that endogenous DNA damage is a major etiological factor in human cancer (Salim et 
al., 2008). In other studies, the correlation between UGS and increase of levels of 
oxidative stress accompanied by continuous DNA damage and repair in urothelial 
carcinomas has been observed repeatedly (Dedon and Tannenbaum, 2004; Botelho 
et al., 2013; Ohinishi et al., 2013). Evidence indicate that UGS-associated SCC might 
arise through a progressive accumulation of genetic changes in epithelial cells. 
Interestingly, the findings obtained revealed the presence in urine of molecules known 
from adult worms and eggs of S. haematobium (Botelho et al., 2013) which were 
considered as carcinogenic chemicals that might interact with host DNA. The 
carcinogenic effect of this estrogen-DNA adducts mediated pathway underlying 
schistosomal-promoted damage to host genes which could partially explain the link 
between UGS and SCC of the bladder. In previous studies using cell lines, Chinese 
Ovary Hamster and HCV29, demonstrated that the co-culture of eggs with cells or 
exposure to parasite antigens, the cells displayed the “hallmarks of cancer” (Botelho 
et al., 2009; Nacif-Pimenta et al., 2019). Probably, this might be related to estrogen-
like metabolites presented in eggs that are release and induce these cellular responses. 
Are these urinary estrogen-like metabolites biomarkers of UGS-associated cancer? 
Biomarkers would be informative in early detection and prognosis of malignancy 
induced by UGS, and the metabolites detected in this study might be a promising 
candidate. Nevertheless, it is required a validation in a larger number of individuals 
with SCC-associated UGS. 
Previously, our research group detected several oxysterol-like metabolites in 
developmental stage of O. viverrini that might be carcinogenic in a similar fashion to 
estrogen-like metabolites (Vale et al., 2013). The fact that its relative O. felineus is not 
considered carcinogenic (IARC, 2012) has raised the question whether these 
metabolites would also be present in parasite and about its potential carcinogenic. In 
order to address this question, we undertook not only LC-MS/MS analysis of 
developmental stages of O. felineus but also biological samples from hamster infected 
with O. felineus (Section III-Chapter 2). The results demonstrated several oxysterol-
like metabolites in the egg and adult stage of adult O. felineus that exhibited marked 
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similarity to oxysterol-like molecules known from O. viverrini. Additionally, it was 
possible observed evidence of interaction of metabolites derived from helminth with 
host DNA leading to DNA adducts detected in sera, urine and especially in bile from 
infected hamsters. The presence of these adducts provides cogent indirect evidence 
of both mutagenic and carcinogenic potential of infection with O. felineus. Therefore, it 
is reasonable hypothesized that liver fluke-derived metabolites might directly damage 
the nuclear DNA of cholangiocytes. On other hand, histopathological studies of liver 
sections from infected hamsters revealed inflammation with severe periductal fibrosis, 
portal area enlargement and changes in the epithelium of the biliary tract characterized 
as biliary intraepithelial neoplasia (BilIN) from different grades. The liver sections 
presented unequivocally BilIN-1 and BilIN-2 and importantly, BilIN-3 that is considered 
a pre-cancerous niche (Zen et al., 2007). Formerly, the role of liver flukes has been 
assigned as a tumor cell growth promoter, whereas the role of NDMA is a mutagenic 
cancer inducer (Thamavit et al. 1978; Maksimova et al., 2016). The data obtained in 
Chapter 2 indicate that precancerous occurs observed in hamsters is independent of 
exposure to an exogenous carcinogen such as NDMA. The consonance biochemical 
and histopathological changes strongly suggested that infection with O. felineus is 
associated with intracellular mechanisms that eventually trigger neoplastic 
transformation of cholangiocytes and promote biliary carcinogenesis, at least in rodent 
model. These findings support earlier observations that O. felineus might induce CCA 
in hamsters (Maksimova et al., 2017). It is reasonable to speculate that the 
pathobiology of O. felineus and O. viverrini infections are similar (Lvova et al., 2012). 
We posit that carcinogenesis associated with O. felineus mimics malignant 
transformation induced by infection with O. viverrini. Given these findings, the role for 
liver flukes is not restricted only to promotion of chronic inflammation, establishment of 
conditions favourable to the promotion and proliferation of incipient cancer cells, and 
tumor growth, but now can be seen to also include mutagenesis capable of initiation 
of the malignant transformation. The accumulation of evidence demonstrating the 
carcinogenic potential of O. felineus suggest that its classification might require 
revision (Pakharukova et al., 2019). Recently, a comparative LC-MS/MS study of 
soluble extracts from liver fluke Fasciola hepatica adult worms (a non-carcinogenic 
agent) from bile ducts of cattle with O. viverrini and O. felineus from experimentally-
infected hamsters (Section VI - Appendix 7) reveal clear differences in regard the 
presence of oxysterols in Fasciola hepatica or Opisthorchis spp.. The oxysterol-like 
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metabolites were minor components of the extract from F. hepatica in contrast to their 
abundance and diversity in Opisthorchis species. We posit that the smaller number of 
oxysterols-like metabolites in Fasciola compared to Opisthorchis species might 
partially explain why definitive carcinogenic potential has not been ascribed to ruminant 
or human fascioliasis. On other hand, the presence of abundant oxysterols in the 
Opisthorchis liver flukes support the notion that they might implicate on liver fluke 
infection-induced biliary malignancy. 
The next step of our work was understanding how the metabolites associated with 
helminth infections were formed (Section III – Chapter 3). Recently, we proposed a 
route to their formation implying the family of CYP450 enzymes (see Section VI-
Appendix 1). The CYP450 isoforms are responsible for formation of estrogen and 
subsequent metabolism and also are involved in the generation of most chemical 
carcinogens that induce genotoxicity and DNA damage (Hammons et al., 1997; 
Guengerich and Shimada, 1998; Nebert and Dalton, 2006). Therefore, we performed 
enzymatic assays in vitro  using commercial starting compounds, glycocholic acid and 
taurochenodeoxycholate sodium, similar to those detected and associated with UGS 
and opisthorchiasis and incubate them with DNA in presence or absence of CYP 
isoforms (CYP1A1, CYP2E1, CYP3A4). The aim was investigating the role of these 
enzymes in activation and/or oxidation of parent compounds and formation of DNA 
adducts. Through these in vitro assays we confirmed the ability of these compounds 
to interact with DNA leading to the formation of DNA adducts. Although CYP450 
isoforms might be involved in formation of some metabolites, apparently, they were not 
crucial during the metabolization of these compounds to form DNA-adducts, since they 
were detected in aliquots that not contained isoforms. Thus, it is reasonable 
hypothesized that oxidized and DNA forms detected were probably generated by non-
enzymatic autoxidation process (Russel, 2000; Björkhem, 2002). Given that some of 
oxidized forms of metabolites were detected in aliquots that presents CYP450 isoforms, 
it is not reasonable rule out that CYP450 might play a role in their oxidation and 
formation (Furge and Guengerich, 2006). Notably, the metabolites and DNA adducts 
previously described (Botelho et al., 2010, 2013; Vale et al., 2013), reported on Section 
III-Chapters 1 and 2, and synthesized during this in vitro assay, were generated in 
absence of CYP450 isoforms. This evidence suggest that the formation of these 
metabolites also might be independent of the parasite CYP450. Importantly, the 
NOVEL THERAPEUTICS APPROACH AGAINST SCHISTOSOMA HAEMATOBIUM AND OPISTHORCHIS 
VIVERRINI AND ASSOCIATED CANCERS (BLADDER CANCER AND CHOLANGIOCARCINOMA) 
207 
 
__________________________________ SECTION IV. DISCUSSION _________________________________ 
findings observed in this assay supported the previous postulate since we have shown 
that metabolites derived from glycocholic acid and taurochenodeoxycholate sodium 
are able to interact with DNA leading to formation of DNA adducts, at least in vitro.  
Despite several control strategies to block their transmission have been developed 
including improvements in sanitation, use of molluskicides, health education, among 
others (Jongsuksuntigul and Imsomboon, 2003; Secor, 2014), and mass drug 
administration programs, opisthorchiasis and UGS remain a public health problem in 
endemic countries (Colley et al., 2014; Ogorodova et al., 2015). The current therapy 
against these helminth infections is based on a single drug, PZQ (WHO, 2006). Is 
current therapy enough to combat the dire complications associated with these 
helminth infections? Despite its safety and efficacy, PZQ alone do not counteract 
pathologies associated with infection including the development of cancer (reviewed 
in Section VI-Appendix 2). To improve the current therapy for these infections and 
taken into consideration the evidence presented in Chapters 1 and 2, we hypothesize 
about developing a novel therapeutic approach with dual mode of action: not only 
target the parasite but might also suppress the formation of metabolites derived from 
parasites. This could lead to improvements in infection-associated pathologies and 
ultimately counteract the development of cancer. With these in mind we proposed a 
novel therapeutic approach based on drug repurposing and combination with 
antioxidants. Why do we select antioxidant biomolecules to use in our novel 
therapeutic approach? Their biological properties might be valuable not only to 
enhance anthelmintic activity but also block the carcinogenesis through inhibition of 
formation of putatively carcinogenic metabolites derived from helminths. Due to difficult 
of S. haematobium grow in rodents (Doenhoff et al., 2009), the effect of novel 
therapeutic approach in elimination of parasite was evaluated in S. mansoni that are 
the most widely schistosome model (Keiser, 2010).  
To evaluate the effect of novel therapeutic approach in elimination of parasite we 
established a mechanical transformation of S. mansoni cercariae into NTS and 
optimize their culture conditions (Section III-Chapter 4). After that, drug sensitivity 
screenings were undertaken using an inverted and automated microscope combined 
with fluorometric-based methods. Comparing the antischistosomal activity of drugs 
alone, AS was more active than PZQ. This finding is consistent with earlier findings 
that showed that AS is more effective against larval stage (Utzinger et al., 2007). 
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Regard to antioxidant alone, Resv demonstrated a moderate activity against NTS. 
Nevertheless, when Resv was combined with PZQ or AS enhance their 
antischistosomal activity and induce a moderate and marked synergistic effect (Section 
III-Chapter 4). The synergy in antischistosomal action might result from increasing the 
action on anthelmintic drugs target or acting concomitantly on different targets (Araújo 
et al., 2008). This evidence was supported not only by optical microscopic but also by 
transmission electron microscopy observations. The ultrastructural analysis 
demonstrated that NTS treated with AS+Resv suffered extensive and severe damage 
in comparison to controls and NTS treated with AS or Resv alone. The tegumental and 
subtegumental regions of these NTS showed severe alterations including disruption of 
tegument, extensive lysis of subtegumental regions with the presence of numerous 
vacuoles with diverse sizes, and loss of the basal membrane. Nonetheless, NTS 
treated with AS alone also showed ultrastructural alterations, including loss of integrity 
of the matrix, and presence of vesicles on the tegument and some tegument disorder 
of larvae treated with Resv. By contrast, the controls presented regular morphology. 
Given these observations, the target of AS, which activity is potentiated when 
combined with Resv, might be the tegument of NTS leading to its disruption and 
extensive lysis of subtegumental regions. This is important, since the tegumental 
damage might lead to disappearance of the immunological camouflage of the parasite  
which, in turn, would expose immunogens and immunogenic epitopes (Shaw and 
Erasmus, 1987; Xiao et al., 2002; Xavier et al., 2014) and might become vulnerable to 
host attack in vivo. The parasite tegument represents the frontline interface between 
host and parasite playing a pivotal role in defence of host immune attack. Also, it has 
essential secretory and nutrient absorption functions (Halton, 1997). The tegument 
disruption induced by AS combined with Resv in vitro might be directly linked to NTS 
death since following tegument damage parasites lost the support for its nutrition. On 
other hand, combination of NAC with AS or PZQ did not translate into a synergistic 
effect. In fact, NAC alone did not present antischistosomal activity. The lack of 
antischistosomal activity of NAC alone was consistent to observed in other report 
(Aires et al., 2012). 
Followed these  encouraging findings we extend the study and evaluated other 
anthelmintic flubendazole (FBZ), anticancer drugs including imatinib (IMT), vandetanib 
(VDT) and trametinib (TMT), and several antioxidants against larval stage and adult 
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worm of S. mansoni (Section III-Chapter 5 and 6). The findings indicated that not only 
do some antioxidants (e.g. Mel, Resv or Flav) improve anthelmintic activity, but they 
exhibited activity per se, leading to high mortality of NTS and adult worms after 
exposure. The most effective antioxidants against both developmental stages were 4-
phenyl-1,2,5-oxadiazole-3-carbonile-2-oxide (OXA) and curcumin (Curc). The 
mechanism of action of these antioxidants remain uncertain. However, it has been 
hypothesized that Curc might be involved in parasite biochemical processes with 
ubiquitin-proteasome pathway might be a possible target. Regard to OXA, its activity 
might be related to inhibition of thioredoxin glutathione reductase (TGR) that plays an 
important role for parasite survival (Sayed et al., 2008). The inhibition of TGR might 
lead to the inactivation of both thioredoxin and glutathione-base defences and the 
accumulation of ROS and RNS species (Sayed et al., 2008). Antioxidants including 
flavone (Flav), melatonin (Mel), dipeptide (H-L-tryptophan-L-serine-OH, DiPept) and 
N-acetylcysteine (NAC) alone demonstrated slight or did not present activity against 
developmental stages of S. mansoni. Nevertheless, the antioxidants might be useful 
to ameliorate the infections-associated pathologies. For example, in other studies it 
was demonstrated that Resv and NAC improve oxidative stress, organ dysfunction and 
restore of enzymatic activity in animal model of schistosomiasis (Soliman et al., 2017). 
All drugs repurposed presented interesting results against larvae or adult worms, 
especially the anticancer drugs. The anthelmintic activity of anticancer drugs might 
derive from the fact that they are kinase inhibitors. Schistosome kinases play a pivotal 
role in different physiological processes as reproduction which is closely associated 
with egg production (Grevelding et al., 2018). Indeed, when adult worms were exposed 
to these drugs the oviposition ceased even if the drug did not lead to their death 
(Section III-Chapter 6). Regard to FBZ, the drug was more active against NTS rather 
than adult worms in contrast to reported by other studies that reported the decrease of 
adult worms recovered from infected animals (Nessim et al., 2000; William et al., 2003). 
Considering the mechanism of action of FBZ, its activity against NTS might be due to 
interaction of the drug with microtubules inhibiting the surface membrane maturation 
of NTS (Wiest et al., 1998; Čáňová, 2017). At least in vitro, the drug did not affect the 
morphology of adult worms which remain alive, however, FBZ ceases the oviposition 
by female worms. Similar to previously observed in Section III-Chapter 4, the results 
obtained by combinations of these drugs and antioxidants were promising and 
demonstrated that even though some antioxidants did not display significant activity 
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against NTS, that does not necessarily indicate that they were not able to enhance 
anthelmintic activity of drugs. Several combinations were classified as synergistic 
against larval stages (e.g. PZQ+Resv or Mel, AS+Resv or NAC, VDT+Flav or Resv) 
(Section III-Chapter 4 and 5), however, in general, this was not translated into adult 
worms where the antischistosomal effect of combinations apparent derived from drugs 
or antioxidants alone (Section III-Chapter 6). The difference might be related to the fact 
that the target in NTS and adult worms are different. Probably, these combinations 
might be suitable for initial stage of infection as prophylaxis or for use in regions with 
intense re-infection levels. The synergism in anthelmintic activity could be a result from 
increased action against anthelmintic drug targets or by acting concomitantly on 
discrete targets (Araújo et al., 2008). By contrast, in combinations classified as 
antagonist (e.g. PZQ+NAC, AS+Mel) the combinations of the compounds might inhibit 
antischistosomal activity of either the drug or the antioxidant. Other studies also report 
the different behaviour of combinations (Keiser et al., 2013; Pakharukova et al., 2018). 
Curiously, the same antioxidant, for example Mel, incubated with different drugs (e.g. 
PZQ+Mel or AS+Mel) displayed different combination indexes (Section III-Chapter 5) 
suggesting that activity of the antioxidant varies depending on the drug used for the 
combination. Additionally, the susceptibility to the drugs and antioxidants alone or in 
combination differ from male to female worms as reported in the literature for several 
drugs (Section III-Chapter 6). For example, it is known that females are less 
susceptible to PZQ or male are less susceptible to AS (Utzinger et al., 2007).  
In general, for both development stages, combinations of AS or anticancer drugs 
plus antioxidants appear to achieve better effect compared to the other combinations. 
Apparently, AS and anticancer drugs present a better profile for the combination of 
different active agents preventing the nullification of the activity of one compound over 
the other. Importantly, drugs and antioxidants either alone or combine not only induce 
morphological alterations that ultimately culminate with death of parasites but also 
affects the oviposition. All drugs evaluated against adult worms ceased oviposition 
either by inducing parasite death or by decoupling. Interestingly, even drugs that did 
not induce severe morphological alterations or decoupling, however, leads to a 
cessation of the oviposition suggesting that reproductive system of the female was 
affected. This feature occurs not only for drugs but also for antioxidants alone (e.g. 
OXA, Curc, Resv, flavone (Flav)) (Section III-Chapter 6). The cessation of oviposition 
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is important since eggs release by female worms are responsible for the formation of 
inflammatory granuloma on target organs, and transmission of these diseases caused 
by schistosomes or opisthorchiids (Sripa et al., 2011; Hussein et al., 2012; Schwartz 
and Fallon, 2018). Regard to combinations and its effect in cessation of oviposition the 
results suggested that they might be related to the effect induced by drug or antioxidant 
alone and not for the combination itself in a similar fashion to observed against adult 
worms. 
The last step of our work consisted in evaluation of the inhibitory effect in formation 
of putative carcinogenic metabolites in vitro by novel therapeutic approach (Section III-
Chapter 7). In this study, not only antioxidants presented interesting results but also 
the novel therapeutic approach (e.g. drug+antioxidant) presented better activity than 
compounds alone. Indeed, antioxidant NAC alone inhibit the formation of most of 
metabolites and DNA adducts in vitro while Resv and drugs (i.e. PZQ and AS) alone 
did not present significant effect. Some studies have been demonstrated that NAC 
reduces semiquinones to their catechol forms and indirectly prevent the formation of 
DNA adducts (Zahid et al., 2010, 2011). Also, Resv also has several important 
characteristics in the context of carcinogenesis prevention: quinone reductase (NQO1) 
inducer, reduce electrophilic compounds, and modulate the activity of CYP450 
enzymes that are responsible for catalyzing the oxidation of estrogen to catechol forms 
(Zahid et al., 2011). Curiously, Resv alone did not present a significant inhibitory effect 
in this context. Regard to AS and PZQ, they are rapidly metabolized to inactive forms 
(Godawska-Matysik and Kieć-Kononowicz, 2006; Morris et al., 2011) which might 
explain the lower effect observed in comparison to combination of drug+antioxidant. 
As mentioned, the inhibitory effect was more pronounced when drugs and antioxidants 
were combined. This increase of effect might be related to ability of Resv in modulate 
activity of enzymes as CYP3A4 preventing the metabolism of AS and PZQ. The most 
promising result was achieved by AS+Resv that lead to almost complete inhibition of 
the formation of metabolites and DNA adducts. Curiously, the combinations of 
drug+drug and antioxidant+antioxidant were not as effective as drug+antioxidants or 
NAC alone. Yet, the combination AS+PZQ achieve better inhibitory effect than drugs 
alone. Both drugs are extensively metabolized by CYP450 isoforms, however, since 
there are two drugs that can be metabolized by the same enzyme, it might occur a 
competition and lead to a lower degree of metabolism of PZQ and AS. Thus, there is 
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more availability of drugs to interact with the starting compounds and inhibit the 
formation of precursor metabolites or DNA adducts.  
We believe that novel therapeutic approach with dual complementary active agents 
developed during this thesis is expected to come successful therapeutic tools. Ideally, 
the data obtained should be use for translational research in order to improve life 
quality and health of populations of endemic areas. Furthermore, a better knowledge 
of the underlying molecular profile of parasite and host will facilitate the development 
of novel therapeutic approach more effective in elimination of parasites and 
ameliorate/prevent the pathologies associated with infection.  
It is our hope that this PhD project draw the attention to these neglected helminth 
diseases that may be re-emerging in developed countries include in Europe.  
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V. Conclusions and future perspectives 
1. Main findings and conclusions of the PhD project 
The main aims of this doctoral thesis were provided deeper insight of the role of 
parasite-derived metabolites in the development of cancer associated with infections 
caused by S. haematobium and Opisthorchis spp. and developed a novel therapeutic 
strategy to combat these infections that presented dual mode of action. 
Regard to the first aim, we believe that the evidence obtained during this thesis 
may be helpful to elucidate the mechanism of carcinogenesis associated with these 
helminth infections. Estrogen metabolites previously described in S. haematobium 
developmental stages (egg and adult worms) and sera from patients with UGS were 
now identified in urine samples from infected individuals. Additionally, the detection of 
derivatives from 8-oxoG urinary excretion of UGS patients indicates a putative 
oxidative action of these metabolites to oxidized DNA. This evidence supports the 
postulate that estrogen-like metabolites mediated the pathway that lead to 
development of SCC through induce DNA damage either by the formation DNA 
adducts or by DNA oxidation. We also demonstrated the potential carcinogenic of O. 
felineus that is not considered carcinogenic but represent a potential public health 
problem in endemic countries. The parasite not only have oxysterol-like metabolites 
similar to those described for O. viverrini but also evidence point out that they interact 
with host DNA leading to DNA adducts. Also, histopathological features demonstrated 
that O. felineus may induce a favorable environment for development of pre-cancerous 
niche, at least in rodent model. Additionally, we demonstrated the ability of similar 
compounds to those associated for UGS and opisthorchiasis to interact with DNA 
leading to formation of DNA adducts in vitro. These findings support the previous 
postulate which indicate that metabolites derived from helminths might play a role in 
initiation of infections-associated carcinogenesis due to DNA damage and open 
avenues for understanding why some helminths cause cancer. 
The novel therapeutic approach with dual mode of action by combining drugs with 
antioxidants achieved promising results. Not only antioxidants by itself were active 
against the larval and adult forms of the parasite but also enhance the antischistosomal 
activity of anthelmintic drugs such as PZQ and AS among others. On other hand, the 
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novel therapeutic strategy was also effective in inhibiting the formation of metabolites 
previously associated with schistosomiasis and opisthorchiasis in vitro. Thus, we have 
shown that the combination of agents with distinct mode of action, as drugs and 
antioxidants, is beneficial in eliminating the parasite, either larval and adult forms, but 
also in preventing the formation of parasite-derived and putatively carcinogenic 
metabolites. The combination of active agents with discrete mode actions seems to be 
effective strategy to improve the therapy against these helmintic infections. Based on 
results obtained and due to their biological properties, antioxidants are a promising 
candidate to use in therapy, not only alone but also combined. The results obtained 
will be important in further studies including in vivo assays. We believe that our results 
may help to improve discussion about novel alternatives to current therapy against 
these dreadful diseases. 
 
2. Future perspectives 
We consider that the results obtained and present in section III of this doctoral 
thesis are promising enough to encourage further research in area of helminth 
infections and its associated cancer. Additionally, further investigation is warranted in 
order to decipher relationships between liver fluke oxysterols and malignancy, 
including opisthorchiasis felinea in humans. These studies will provide further 
knowledge of opisthorchiasis-associated carcinogenesis. In future, it will be important 
perform studies using informative cell lines in order to evaluate the potential 
carcinogenic of metabolites derived from helminths. On other hand, the effect of novel 
therapeutic approach should be also evaluated in cell lines, in vivo and in other species 
including S. haematobium and Opisthorchis spp.. Further studies are required to 
elucidate the mechanism of drugs and antioxidants alone and how they induce 
synergism when are combined. Furthermore, it is important understand the targets of 
different developmental stages that will help to development a more targeted and 
effective therapy. During this thesis we performed preliminary studies regarding to 
inhibitory effect in formation of metabolites and DNA adducts by novel therapeutic 
strategy. Nevertheless, its inhibitory effect should be also evaluated in the cellular 
environment and in vivo to assess its effect on amelioration of infection-associated 
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pathologies. Exploitation of parasite-derived antigens to use in immunotherapy against 
these helminth infections should also be considered. 
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Table S1. Oviposition expressed as the number of eggs deposited per worm during 
in vitro assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1h 17h 24h 48h 72h 
 Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
Compounds alone 
control 6.0 ± 0.0 29.3 ± 0.6 29.7 ± 0.6 70.7 ± 0.6 108.3 ± 2.3 
DMSO 0.1% 107.0 ± 13.3 137.2 ± 39.2 161.5 ± 36.2 263.7 ± 4.7 383.5 ± 79.9 
PZQ 26.7 ± 1.5 27.7 ± 1.5 29.7 ± 1.5 27.3 ± 2.1 29.3 ± 1.5 
AS 50.3 ± 1.5 71.3 ± 1.5 73.3 ± 2.5 73.0 ± 2.0 75.7 ± 2.5 
FBZ 33.7 ± 1.2 39.0 ± 1.7 31.7 ± 1.2 41.7 ± 1.5 41.7 ± 1.5 
TMT 41.3 ± 0.6 41.0 ±1.0 43.0 ± 1.0 42.7 ± 1.2 42.7 ± 1.2 
VDT 4.3 ± 1.5 4.7 ± 1.5 4.0 ± 1.0 4.3 ± 0.6 5.0 ± 2.0 
IMT 30.7 ± 2.1 34.0 ± 2.0 34.7 ± 1.5 36.3 ± 1.5 36.0 ± 3.0 
Resv 17.3 ± 0.6 17.3 ± 1.5 34.3 ± 3.1 34.3 ± 3.5 34.3 ± 3.1 
NAC 59.3 ± 3.8 138.7 ± 2.5 173.0 ± 3.6 261.0 ± 2.0 322.0 ± 2.6 
Flav 85.7 ± 0.6 88.0 ± 8.2 88.0 ± 8.2 88.0 ± 2.6 91.3 ± 1.5 
Mel 69.7 ± 0.6 145.7 ± 3.5 192.3 ± 4.9 249.7 ± 1.5 307.0 ± 2.6 
DiPept 41.3 ± 2.1 98.0 ± 1.0 105.7 ± 1.5 127.3 ± 2.5 167.0 ± 2.0 
OXA 2.7 ± 0.6 3.0 ± 1.0 3.3 ± 0.6 3.3 ± 1.5 3.3 ± 1.5 
Curc 52.7 ± 1.5 52.7 ± 1.5 52.7 ± 1.5 52.7 ± 1.5 52.7 ± 1.5 
Drug+AntiOx 
PZQ+Resv 58.7 ± 1.5 60.3 ± 2.1 61.3 ± 1.5 61.0 ± 2.0 61.3 ± 1.5 
AS+Resv 55.0 ± 2.0 56.3 ± 1.5 61.3 ± 2.3 61.7 ± 1.5 61.7 ± 2.3 
AS+NAC 59.3 ± 2.1 75.3 ± 3.8 76.0 ± 2.6 76.3 ± 1.5 76.7 ± 1.5 
AS+DiPept 50.7 ± 3.4 70.7 ± 1.2 72.3 ± 3.8 88.0 ± 1.0 88.0 ± 1.0 
AS+OXA 4.7 ± 0.6 4.7 ± 0.6 4.7 ± 0.6 4.7 ± 0.6 4.7 ± 0.6 
AS+Curc 49.3 ± 2.1  49.0 ± 2.6 49.0 ± 2.6 49.0 ± 2.6 49.0 ± 2.6 
AS+Flav 43.3 ± 1.2 53.3 ± 1.2 53.3 ± 1.2 53.3 ± 1.2 53.3 ± 1.2 
AS+Mel 16.7 ± 1.2 23.0 ± 1.0 23.0 ± 1.0 23.0 ± 1.0 23.0 ± 1.0 
FBZ+Flav 41.7 ± 1.1 42.3 ± 2.1 47.7 ±1.2 47.0 ± 1.5 58.7 ± 4.0 
FBZ+Mel 83.0 ± 2.0 127.0 ± 0.6 154.7 ± 4.9 155.3 ± 7.4 158.3 ± 1.2 
IMT+Flav 57.7 ± 1.1 58.7 ± 1.2 57.0 ± 1.0 57.7 ± 1.5 57.3 ± 1.5 
IMT+Mel 67.0 ± 1.0 71.7 ± 1.5 71.7 ± 1.5 71.7 ± 1.5 71.7 ± 1.5 
TMT+Mel 22.3 ± 1.5 26.3 ± 2.1 25.0 ± 1.0 25.0 ± 1.0 25.0 ± 1.0 
TMT+Flav 69.3 ± 0.6 71.0 ± 1.0 71.7 ± 1.5 71.7 ± 1.5 69.3 ± 1.2 
VDT+Resv 28.0 ± 1.7 31.0 ± 1.7 31.0 ± 1.7 31.0 ± 1.7 33.7 ± 3.2 
VDT+Flav 43.3 ± 2.1 43.3 ± 2.1 43.3 ± 2.1 43.3 ± 2.1 43.3 ± 2.1 
AntiOx+AntiOx 
OXA+Curc 24.0 ± 1.7 24.0 ± 1.7 24.0 ± 1.7 24.0 ± 1.7 24.0 ± 1.7 
Flav+NAC 61.7 ± 3.1 59.0 ± 1.0 65.0 ± 2.0 62.3 ± 0,6 80.3 ± 1.5 
Flav+Mel 29.3 ± 1.2 32.7 ± 1.5 32.0 ± 2.0 40.3 ± 0,6 40.3 ± 2.5 
Flav+DiPept 57.7 ± 0.6 72.7 ± 1.2 73.7 ± 0.6 73.0 ± 2.0 81.0 ± 2.6 
Mel+Dipept 44.7 ± 1.5 86.0 ± 3.6 111.0 ± 3.0 152.0 ± 1.7 217.0 ± 9.8 
Mel+NAC 52.3 ± 1.2 111.3 ± 0.6 143.0 ± 2.6 171.7 ± 1.2 205.0 ± 2.0 
Dipept+NAC 38.0 ± 2.0 73.7 ± 0.6 86.7 ± 0.6 95.0 ± 1.0 137.3 ± 1.5 
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Figure S1. Representative micrographs of adult worms following 72h of exposure to anthelmintic 
[praziquantel (PZQ), artesunate (AS), flubendazole (FBZ)], anticancer drugs [imatinib (IMT), trametinib 
(TMT) and vandetanib (VDT)], antioxidants [(4-phenyl-1,2,5-oxadiazole-3-carbonile,2-oxide (OXA), N-
acetylcysteine (NAC), resveratrol (Resv), flavone (Flav), H-Trp-Ser-OH (DiPept), melatonin (Mel)] alone 
and combined (1:1) at 100 μM. 
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Figure S1: Mass spectra and m/z obtained for different samples analyzed by LC-
MS/MS. 
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Appendix 7 
Spectrometric profiles liver flukes Opisthorchis and Fasciola provide insight into 
infection-induced carcinogenesis (submitted). 
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Fasciola provide insight into infection-induced carcinogenesis 
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Abstract 
Chronic infections with the flatworm parasites Opisthorchis viverrini, Clonorchis 
sinensis and Schistosoma haematobium are classified as group 1 biological 
carcinogens, i.e. definitive causes of cancer. In addition, we reported findings that 
support the inclusion of Opisthorchis felineus in this list of biological carcinogens. By 
contrast, infections with close phylogenetic relatives including Fasciola hepatica have 
not been associated with carcinogenesis. Earlier reports revealed of oxysterol 
metabolites of Opisthorchis liver fluke origin conjugated with DNA bases, suggesting 
that the generation of these DNA-adducts may underlie the mutagenicity and 
carcinogenicity of the infection with these food-borne pathogens. Here we employed 
liquid chromatography-mass spectrometry (LC-MS/MS) to investigate, compare and 
contrast spectrograms of soluble extracts from F. hepatica adult worms from bile ducts 
of cattle with those from O. viverrini and O. felineus from experimentally-infected 
hamsters. F. hepatica and Opisthorchis spp. shared common compounds including 
oxysterol-like metabolites, bile acids and DNA-adducts, but the spectrometric profiles 
of Fasciola hepatica included far fewer compounds than Opisthorchis species. By this 
way, we can speculate why chronic infection with F. hepatica has not been associated 
with liver carcinogenesis. These findings support the postulate that oxysterol-like 
metabolites of parasite origin could be related to carcinogenesis associated to infection 
and they point to a molecular basis for the differences among major groups of liver 
flukes concerning infection-induced malignancy. 
Author Summary 
Several species of trematodes are parasites of the human hepatobiliary tract. 
Infection with two of these flukes, Clonorchis sinensis and Opisthorchis viverrini, 
freshwater fish-borne parasites that occur in East Asia is classified as group 1 
carcinogens by the International Agency for Research on Cancer (IARC), i.e. definitive 
causes of cancer in humans. By contrast, infection with a different liver fluke, Fasciola 
hepatica, does not lead to malignant transformation of the biliary tract. Given the close 
phylogeny of all three parasites, this difference in carcinogenicity is intriguing and, if 
explained, likely of value in novel therapeutic approaches. The importance of the 
current findings is informative because they present a mass spectrometric analysis and 
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catalog of the similarities and differences between fluke of the genus Opisthorchis and 
F. hepatica, potentially identifying carcinogenic metabolites of liver fluke origin. These 
metabolites can be expected to provide deeper understanding of helminth infection 
induced malignancy.  
Keywords 
Fasciola hepatica, Opisthorchis viverrini; Opisthorchis felineus; oxysterols; DNA 
adducts  
 
Introduction 
More than 20% of cancer in the developing world are caused by infections [1]. The 
World Health Organization’s International Agency for Research on Cancer (IARC) 
recognizes the infection with about 12 pathogens as group 1 biological carcinogens, 
i.e., definitive causes of cancer. These group 1 agents include three helminth 
parasites, specifically the fish-borne trematodes (FZT) Opisthorchis viverrini and 
Clonorchis sinensis and the blood fluke, Schistosoma haematobium [2]. In addition, 
we reported findings from hamster infection that support the inclusion of Opisthorchis 
felineus, also an FZT, to this list of biological carcinogens and definitive cause of 
cholangiocarcinoma [3]. We hypothesised that these helminths produce and release 
derivatives of oestrogens and oxysterols that promote oxidation of host DNA and have 
the ability of parasite metabolites to directly promote DNA lesions adducts and 
mutations that ultimately lead to cholangiocarcinoma [1,3-6]. The findings supported 
the postulate that these infection-associated cancers originate from a biological and/ 
or chemical insult followed by chronic inflammation, fibrosis, and a change in the tissue 
microenvironment that leads to a pre-cancerous niche [7,8].   Paradoxically, infections 
with other close phylogenetic relatives of these carcinogenic helminths, also food 
borne trematodes of the Phylum Platyhelminthes (Table 1), have not been categorized 
as group 1 biological carcinogens [9-15].
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Table 1. Comparison of morphology, life cycle and pathogenesis between Fasciola hepatica and 
Opisthorchis species.
  
 
 
Fasciola spp. 
 
 
 
Opisthorchis spp. 
MORPHOLOGY 
(ADULT WORM) 
· Flatworms; leaf-like; 20-30 mm · 5-10 mm 
LIFE CYCLE · Eggs embryonate in water releasing miracidia, 
which invade a suitable snail intermediate 
host. 
· Cercaria released from the snail encysts as 
metacercaria on aquatic plants. 
· After ingestion, the metacercaria excysts in the 
duodenum and migrates through the intestinal 
wall, the peritoneal cavity, and the liver 
parenchyma into biliary ducts, where 
development to the hermaphroditic adult stage 
occurs. 
· Starts laying eggs 3-4 months’ post-infection. 
Long lived 
· Eggs are ingested by freshwater snails release 
miracidia, which undergo several 
developmental stages in the snail. 
· Cercaria released form the snail encysts as 
metacercaria in fish. 
· After ingestion, the metacercaria excysts in the 
duodenum and ascends though the ampulla de 
Vater into the biliary tree where the liver fluke 
develops within the lumen of the bile ducts into 
the hermaphroditic adult form. 
· Starts laying eggs 3-4 weeks later. Long lived. 
 
PHASES OF 
INFECTION 
Acute: parenchymal stage; fluke migration into 
the bile duct where parasite ingests hepatic 
tissue; causes parenchymal destruction and 
immunologic and inflammatory reactions. 
Chronic: develops months after initial 
infection; consists of inflammation and 
hyperplasia of the epithelium and fibrosis; 
caused by the adult liver flukes residing in the 
bile ducts. 
· Early stage no detectable change in the biliary 
epithelium and periductal areas of the liver. 
Chronic: desquamation of the biliary 
epithelium; epithelial hyperplasia; bile duct 
hyperplasia; periductal fibrosis; cellular 
infiltrates consist if lymphocytes, monocytes, 
eosinophils and some plasma cells; 
granulomatous inflammation; Histological 
analysis of liver sections from hamsters infected 
with O. felineus confirmed portal area 
enlargement, inflammation with severe 
periductal fibrosis and changes in the epithelium 
of the biliary tract characterized as biliary 
intraepithelial neoplasia, BilIN [3]. 
 
RELATION TO 
CANCER 
· Unclear; no direct relationship has been 
definitively proved between the chronic 
infection and cancer. 
· Experimental data supporting opposing 
effects: 
Tumor growth stimulation: and proliferation 
of hepatocytes in acute phase of infection 
where juvenile flukes migrate through the 
parenchyma of the liver, provoking intense 
inflammatory response to antigens and 
secretory-excretory products from the flukes; 
induces proliferation of adjacent cells; 
accumulation of inflammatory cells capable of 
inducing DNA damage via ROS (ethene 
aducts) [9,10]. 
Tumor inhibition: observed in chronic phase 
of infection whereas acute infection may 
increase the metabolizing enzymes in the liver, 
and this decrease the activation of exogenous 
carcinogens, chronic infection reduces the 
metabolizing activity [11]. 
 
· Group 1 biological agent; infection is directly 
related to cholangiocarcinoma (CCA). 
 
 
· Postulated that Opisthorchis spp produces 
oxysterol-like metabolites that may act as 
initiators of the carcinogenesis associated to 
infection. 
OTHER RELEVANT 
ASPECTS 
Ectopic infections misdiagnosed as cancer; 
leads to increase of oxidative stress and lipid 
peroxidation; alters the antioxidant enzymatic 
system responsible to eliminate excess of 
ROS; mutability of CYP 2A5 [12]. 
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For instance, Fasciola hepatica has a wide geographical range, causes major 
economic loss in sheep and cattle worldwide, and also is an important food borne 
trematodes (FBT) pathogen of humans [16]. Despite fascioliasis can induce host DNA 
damage through action of reactive nitric species (RNS) or oxygen species (ROS) 
[15,17], however, the infection is not associated to carcinogenesis. Seeking new 
insights in the apparent paradox of differences in carcinogenicity among closely related 
FBZ, here we conducted an analysis of soluble extracts of adult worms of F. hepatica, 
O. viverrini and O. felineus by liquid chromatography coupled with mass spectrometry 
(LC-MS/MS). Remarkably, the LC-MS/MS chromatograms for each liver fluke species 
exhibited clear differences in regard the presence of oxysterols. These metabolites 
were minor components of the extract from F. hepatica, in contrast to the abundance 
and diversity of forms of oxysterols in O. viverrini and O. felineus. The presence of 
abundant oxysterols in the metabolites of Opisthorchis liver flukes support the notion 
that represent initiators of liver fluke infection-induced biliary tract malignancy.  
 
 
Material and methods 
Ethics Statement. Procedures undertaken complied with The Code of Ethics of the 
World Medical Association (Declaration of Helsinki) for animal experiments 
http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm. Syrian 
hamsters (Mesocricetus auratus) were purchased from the stock of the Puschino 
Animal Facility (Russia) and bred at the Animal Facility of the ICG SB RAS 
(RFMEFI61914X0005) (Russia). The hamsters were maintained according to 
protocols approved by the Committee on the Ethics of Animal Experiments of the 
Institute of Cytology and Genetics (Permit Number: 25 of 12.12.2014). 
 
Soluble extracts from F. hepatica, O. viverrini and O. felineus adult liver flukes. 
Adult worms of F. hepatica were obtained from the bile ducts of infected cattle at a 
local slaughterhouse [18]. It should be noted that the animals were processed as part 
of normal work of the slaughterhouse. O. viverrini and O. felineus were obtained as 
previously described [3,4]. In brief, metacercariae of Opisthorchis species were 
obtained from naturally infected cyprinoid fish in Khon Kaen province, Thailand or from 
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naturally infected fish (Leuciscus idus) in the Ob River near the city of Novosibirsk, 
Siberia Russia, respectively. The fish were digested with pepsin-HCl [3]. Fifty 
metacercariae were used to infect hamsters (Mesocricetus auratus) and three months 
after infection, the animals were euthanized and adult O. viverrini or O. felineus flukes 
recovered from their bile ducts. The worms were washed extensively in phosphate 
buffered saline (PBS, pH 7.4) supplemented with 100 μg/mL streptomycin and 100 
U/mL penicillin G and cultured overnight in serum free RPMI-1640 medium (Lonza, 
Basel, Switzerland) containing 1% glucose, and protease inhibitors (0.1 mM 
phenylmethanesulfonyl fluoride, 2 μM E-64 and 10μM leupeptin) (Sigma-Aldrich, St. 
Louis, Missouri) at 37 °C, 5% CO2.  
Soluble extracts from all samples were prepared by sonication (5 x 5s burst, output 
cycle 4, Branson Sonifier 450, Germany) in PBS supplemented with protease inhibitors 
[500 μM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), 0.3 μM 
aprotinin, 10 μM E-64, 10 μM bestatin and 10 μM leupeptin] (M221, Amresco, Solon, 
OH, USA), followed by 30 min centrifugation at 10,000 rpm, 4 ºC. The protein 
concentration of supernatants was determined using a commercial kit. Ascorbic acid 
was added to 1 mg/ml to these extracts, which were stored in aliquots at -80 ºC [3,4].  
 
Sample preparation and LC-MS/MS analysis. Samples were prepared and 
processed using liquid chromatography diode array detection electron spray ionization 
mass spectrometry, as described [3-5]. Due to the acceptable chromatographic 
performance of methanol as the solvent in terms of separation and sensitivity, with 
short gradient times [19], this solvent was added up to 20% (v/v). High performance 
liquid chromatography coupled with mass spectrometer was employed to investigate 
molecular species from liver flukes, with samples of 25 μL injected into the LC-MS/MS 
instrument for analysis. The mass analysis was performed within an LTQ Orbitrap XL 
mass spectrometer (Thermo Fischer Scientific, Bremen, Germany), fitted with an 
ultraviolet (UV) photo diode array (PDA) detector. Analysis involved a Macherey-Nagel 
Nucleosil C18-column (250 mm x 4 mm internal diameter; 5 μm particle diameter, end-
capped), proceeding at a flow rate of 0.3 ml/min. The capillary voltage of the 
electrospray ionization was 28 kW, capillary temperature was 310 ºC, flow rates of the 
sheath gas and auxiliary N2 were set to 40 and 10 (arbitrary unit as provided by the 
software settings), respectively, and gas temperature was 275 ºC [3-5]. The mobile 
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phase consisted of 1% formic acid in water (A)/acetonitrile (B) mixtures. Eluates were 
monitored for 75 min, run with a mobile phase gradient of 0-5 min, 100% A; 5-10 min, 
linear gradient from 100% to 80% A, 10-15 min 80% A, 15-50 min, linear gradient from 
80% to 40% A; 50-65 min, 40% A; 65-75 min, linear gradient from 40% to 100% B.  
Washing for 15 min with acetonitrile was carried out to stabilize the column. Data were 
collected in negative electrospray ionization negative mode scanning a mass to charge 
ratio (m/z) range of 50-2000. 
 
Results 
Both species of Opisthorchis shared identical mass spectra profiles.  
We have developed a sensitive LC-MS/MS-based protocol to identify new steroids-
derived molecules not only in extracts of helminth parasites [3,4], but also from 
experimental infected rodents [4] and naturally-infected humans [5]. Extracts obtained 
from F. hepatica adult worms were analyzed in order to provide insights related to their 
composition and complexity. 
Comparing data obtained for O. viverrini with O. felineus we observed that both 
these liver flukes displayed highly similar mass spectra (MS) and shared most peaks 
detected (indicated in grey in Fig 1) which were attributed to oxysterol-like metabolites, 
e.g. mass/charge (m/z) 356, 307, bile acids in oxidized form, e.g. m/z 443, 479, 488 
and DNA-adducts, e.g. m/z 599, 639, 667 [3,4].    
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Fig 1. Comparison of mass spectral profiles obtained for Fasciola hepatica and Opisthorchis 
spp. Panel A, common m/z between the three liver flukes; panel B, major differences among the liver 
flukes. 
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F. hepatica extracts exhibited striking differences to those of the Opisthorchis 
species. 
Notable differences were apparent among the MS profiles of F. hepatica and the 
Opisthorchis species. Most of compounds present in both Opisthorchis species were 
absent from F. hepatica, specifically m/z 356, 357, 425 and 307. Remarkably, these 
specific compounds were attributed to be oxysterols with ability to react with host DNA 
as described [3]. The MS profile of F. hepatica was much more complex than those 
obtained for Opisthorchis spp. (Fig 1). The major differences were observed at 
retention intervals of approximately 24, 32, and 40 min – as indicated in orange, yellow 
and blue, respectively, on the chromatographs (Fig 1). On these retention times, F. 
hepatica showed greater number of compounds in comparison to those observed on 
Opisthorchis species (Fig 1 and Table 2). Remarkably, most of these compounds were 
detected only in F. hepatica extracts (Table 2). 
Unlike Opisthorchis, F. hepatica displayed more compounds with elevated m/z 
(between 600 and 800), mostly between retention interval of 38 to 42 min (Table 2), 
which might suggest that they are more complex than the majority of those detected 
on Opisthorchis spp.  
Nonetheless, F. hepatica and Opisthorchis spp. shared several common 
compounds at retention interval of 58-64 min (signed by green in Fig 1 and Table 2). 
These compounds have been ascribed previously to oxysterol-like metabolite (e.g. m/z 
325), bile acids (e.g. m/z 571) and as well as DNA-adducts (m/z 599) [4]. To reiterate, 
however, these were fewer of these compounds in F. hepatica compared to 
Opisthorchis spp.  
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Table 2. Comparison of mass/charge (m/z) obtained for Fasciola hepatica during this study with 
Opisthorchis spp. previously reported for O. viverrini [3,4] and O. felineus [3]. The structures of common 
m/z (signed at green) are depicted on S1 Table. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Retention time (min) m/z Fh Ov Of 
17.64 337.08 ✓  ✓   
23.24 320.17 ✓    
23.25 353.13 ✓    
23.95 293.12 ✓    
24.17 245.12 ✓    
 414.22 ✓    
24.26 279.14 ✓    
 676.30 ✓    
24.36 305.08 ✓    
24.41 245.12 ✓    
24.75 229.16 ✓    
 201.13 ✓    
25.08 227.14 ✓    
25.13 259.13 ✓    
 291.10 ✓    
 319.10 ✓    
25.41 358.20 ✓    
25.54 318.11 ✓    
28.12 429.23 ✓    
 465.20 ✓    
 543.22 ✓    
32.89 443.24 ✓    
37.65 301.07 ✓    
38.18 629.30 ✓    
39.50 316.17 ✓    
 535.23 ✓    
40.50 677.50 ✓    
 713.48 ✓    
 724.51 ✓    
41.70 790.58 ✓    
 826.56 ✓    
 837.59 ✓    
51.02 447.14 ✓    
54.86 321.18 ✓    
58.70 255.23 ✓  ✓  ✓  
58.92 407.28 ✓  ✓  ✓  
59.93 571.29 ✓  ✓  ✓  
61.06 311.17 ✓  ✓  ✓  
64.25 325.19 ✓  ✓  ✓  
64.15 599.32 ✓  ✓  ✓  
70.16 367.25 ✓    
77.95 339.20 ✓  ✓  ✓  
76.38 391.29 ✓    
81.63 465.31 ✓    
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Discussion 
Both chronic infection with Fasciola spp. and Opisthorchis spp. could lead to 
fibrosis, hyperplasia and biliary stasis [3,10,21-23]. However, an association between 
fascioliasis and cancer remains controversial and not definitely established [10]. Thus, 
we decided to investigate extracts of adult worms of F. hepatica and compare with data 
previously obtained for Opisthorchis spp. We aimed to address the following questions: 
1) does F. hepatica synthesize and excrete metabolites that promote direct damage 
on host DNA, and 2) if F. hepatica induces DNA damage, why has fascioliasis not been 
associated with liver cancer in ungulates or indeed humans? The MS profile of F. 
hepatica was found to be far more complex, showing an elevated number of 
compounds with an elevated m/z rather than Opisthorchis spp. This suggested that 
metabolic process that occur in F. hepatica are dissimilar to those in Opisthorchis spp.  
The LC-MS/MS analysis also revealed a great diversity of compounds with different 
m/z. This diversity might reflect fragmentation of a number of compounds, detected 
here as lower m/z fragments of other compounds. However, we cannot conclude that 
these are not novel compounds. In addition, some of these compounds might be 
precursors of known compounds recorded previously [3,4]. Compounds of F. hepatica 
might be related to the different migratory route of the parasite to the biliary tree. Unlike 
Opisthorchis spp., newly excysted juveniles of F. hepatica exit the lumen of the small 
intestine, transverse the intestinal wall and migrate through the abdominal cavity to the 
Glisson´s capsule of the liver [20,24]. This parasite might deploy more complex 
biochemical processes and secretions, including the secretion of cathepsins [25-27] to 
accomplish this elaborate organ and tissue migration. The juvenile F. hepatica infects 
the liver by directly penetrating the Glisson’s capsule from the abdominal cavity, and 
thereafter burrows through the hepatic parenchyma to the bile ducts where it eventually 
matures into the egg-laying adult worm (S1A Fig) [20]. Components detected in the 
extracts of F. hepatica might be related with digestion of host tissues including blood 
such as hemoglobin, albumin and immunoglobin to support reproductive process 
including synthesis of eggs [20]. This might not only explain the complex MS profile 
but also the compounds with elevated m/z as well as lower m/z that could be 
associated with free amino acids. On other hand, most of the compounds observed 
from 23 to 57 minutes were specific of F. hepatica, i.e. not present in Opisthorchis. 
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Juvenile Opisthorchis flukes ascend from the duodenum directly into the lumen of 
biliary tree [23,28].  
Glycocholic acid in the mammalian small intestine triggers the excystment of the 
metacercaria and emergence of F. hepatica juvenile flukes stimulating the exit of the 
parasite from the gut lumen and its migration to the abdominal cavity. Intriguingly, the 
juvenile F. hepatica did not survive in bile-containing solutions whereas the adult fluke 
resides in the bile ducts, bathed in bile [29]. Differences in the nature of the juvenile 
versus adult tegument of F. hepatica and the selectivity and the permeability of 
glycocalyx of the tegument may underpin these stage specific differences [29]. The 
complexity of the tegument, a complex metabolically active and highly glycosylated 
biological matrix [30] might also underpin complexity of F. hepatica MS profile and its 
components.  
Both F. hepatica and the two Opisthorchis species shared some identical 
compounds that were previously attributed to oxysterol-like metabolites, bile acids and 
DNA-adducts. This is feasible since all three flukes live within the biliary tree. There is 
evidence that F. hepatica induces DNA damage through the action of mutational-
mediators [9,31]. The presence of DNA adducts in tissue does not necessarily imply a 
specific tumorigenic risk for the host tissue. Other factors such as DNA repair and cell 
proliferation key roles players in determining the overall carcinogenic risk [32]. An 
association between fascioliasis and cancer has only been suggested from in vitro 
studies and, thus far, there have not been satisfactory reports of human cases of bile 
duct cancer due to chronic infection with F. hepatica [10,14,33-35]. Therefore, there is 
a lack of cogent evidence that relate fascioliasis with cancer [10]. By contrast, a number 
of reports posit opposing effects, i.e. tumor growth stimulation and inhibition. Tumor 
growth stimulation and proliferation of hepatocytes has been observed during acute 
phase of infection where larval flukes migrate through the parenchyma of the liver and 
provoke marked inflammation [12,17]. In turn, the chronic inflammation increases 
oxidative stress that can overwhelm antioxidant system homeostasis to dampen 
reactive oxygen species and consequent oxidative modification of lipids, nucleic acids 
and proteins [9]. Like fascioliasis, opisthorchiasis is characterized by elevated oxidative 
stress and altered the antioxidant systems [9,11]. Tumor inhibition has been noted 
during the chronic phase of fascioliasis that may dampen the liver metabolizing activity 
[12]. We also documented that infection with O. felineus induces BilIN. The 
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consonance of findings that the presence of new metabolites and of BilIN-1 and BilIN-
2 indicates that O. felineus infection induces neoplastic transformation of 
cholangiocytes and can be expected to promote growth of biliary cancers [3]. Whereas 
acute F. hepatica infection may increase the metabolizing enzymes in liver and thus 
increase the activation of exogenous carcinogens [22], chronic infection may reduce 
hepatic metabolizing activity [12]. It is noteworthy that chronic infection with F. hepatica 
in a rat model suppressed N-nitrosodimethyldiamine-induced carcinogenesis, 
suggesting a parasite-induced inhibition of carcinogenesis in the liver of rodents 
experimentally infected with F. hepatica [17]. All these hypotheses require further 
investigation and experimental validation. This study aimed to characterize the 
differences between Fasciola and Opisthorchis with a view to identifying the parasite-
derived compound that results in the different pathogenic outcomes after infection with 
these two parasites. Not only is this important to understanding the mechanism of 
pathology, with a view to perhaps developing appropriate therapeutics in the future, 
but it would also provide information to understand how two flukes have adapted to 
induce such different outcomes in their hosts. 
Fasciola hepatica displayed more complex mass spectra profile that the 
Opisthorchis species and several specific compounds that might be related to its 
complex route of migration to the biliary tract. Nonetheless, F. hepatica shared several 
compounds with Opisthorchis, which are related to oxysterols, bile acids and DNA-
adducts. The presence of only a few common compounds might explain why 
fascioliasis has not been causally linked with liver cancer. Indeed, we posit that fewer 
oxysterol-like metabolites might (partially) explain why definitive carcinogenic potential 
has not been ascribed to ruminant or human fascioliasis (S1B Fig). On the other hand, 
it has been shown that F. hepatica could suppress reactivity of liver carcinogens.  
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S1 Table. Structures of m/z common to Fasciola hepatica and Opisthorchis 
species. 
S1A Fig. Different routes that liver flukes undergo to reach the biliary tree. F. 
hepatica (signed at blue) transverses the intestinal wall and migrates through 
peritoneum to the Glisson´s capsule of the liver, perforate the capsule enters the liver 
parenchyma and migrates to the biliary tree. In contrast, Opisthorchis spp. juveniles 
pass through the stomach to the duodenum with ingested fish, after which they ascend 
into the biliary tract through the ampulla de Vater (signed at yellow). This might 
constitute the major reason for complexity of mass spectra profile of F. hepatica.  
S1B Fig. Adult liver flukes O. viverrini and O. felineus produces oxysterol-like 
metabolites that interact with host chromosomal DNA to form DNA-adducts and 
forms of biliary intraepithelial neoplasia that conducive to cholangiocarcinoma. 
F. hepatica also elaborates oxysterol-like metabolites, but at much lower number, 
which might be explain, at least in part, why infection with this parasite fails to induce 
malignancy. 
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Supplementary Table S1. Structures of m/z common to Fasciola hepatica and Opisthorchis 
species. 
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S1A Fig. Different routes that liver flukes undergo to reach the biliary tree. F. hepatica (signed at 
blue) transverses the intestinal wall and migrates through peritoneum to the Glisson´s capsule of the 
liver, perforate the capsule enters the liver parenchyma and migrates to the biliary tree. In contrast, 
Opisthorchis spp. juveniles pass through the stomach to the duodenum with ingested fish, after which 
they ascend into the biliary tract through the ampulla de Vater (signed at yellow). This might constitute 
the major reason for complexity of mass spectra profile of F. hepatica.  
 
 
 
S1B Fig. Adult liver flukes O. viverrini and O. felineus produces oxysterol-like metabolites that 
interact with host chromosomal DNA to form DNA-adducts and forms of biliary intraepithelial 
neoplasia that conducive to cholangiocarcinoma. F. hepatica also elaborates oxysterol-like 
metabolites, but at much lower number, which might be explain, at least in part, why infection with this 
parasite fails to induce malignancy. 
 
